NZ336836A - Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments - Google Patents
Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatmentsInfo
- Publication number
- NZ336836A NZ336836A NZ336836A NZ33683698A NZ336836A NZ 336836 A NZ336836 A NZ 336836A NZ 336836 A NZ336836 A NZ 336836A NZ 33683698 A NZ33683698 A NZ 33683698A NZ 336836 A NZ336836 A NZ 336836A
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- hydrogen
- alkoxy
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims description 69
- -1 Arylsulfonyl hydroxamic Chemical compound 0.000 title claims description 67
- 238000011282 treatment Methods 0.000 title claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 98
- 125000003118 aryl group Chemical group 0.000 claims description 83
- 125000000217 alkyl group Chemical group 0.000 claims description 81
- ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 claims description 76
- 239000001257 hydrogen Substances 0.000 claims description 72
- 229910052739 hydrogen Inorganic materials 0.000 claims description 72
- 239000000203 mixture Substances 0.000 claims description 65
- 125000001072 heteroaryl group Chemical group 0.000 claims description 56
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 47
- 125000003545 alkoxy group Chemical group 0.000 claims description 36
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 30
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- 125000005842 heteroatom Chemical group 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 17
- 125000004104 aryloxy group Chemical group 0.000 claims description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 17
- 230000005764 inhibitory process Effects 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 125000002757 morpholinyl group Chemical group 0.000 claims description 17
- 239000001301 oxygen Substances 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 17
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 16
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 16
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 150000004702 methyl esters Chemical class 0.000 claims description 14
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 13
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 13
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 13
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 13
- 125000002393 azetidinyl group Chemical group 0.000 claims description 12
- 125000003386 piperidinyl group Chemical group 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000005110 aryl thio group Chemical group 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 125000004414 alkyl thio group Chemical group 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- 125000004423 acyloxy group Chemical group 0.000 claims description 8
- 125000001769 aryl amino group Chemical group 0.000 claims description 8
- 125000005936 piperidyl group Chemical group 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 208000025865 Ulcer Diseases 0.000 claims description 7
- 206010003246 arthritis Diseases 0.000 claims description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 7
- 230000036269 ulceration Effects 0.000 claims description 7
- 229910052684 Cerium Inorganic materials 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 206010040070 Septic Shock Diseases 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 231100000433 cytotoxic Toxicity 0.000 claims description 6
- 230000001472 cytotoxic effect Effects 0.000 claims description 6
- 125000005368 heteroarylthio group Chemical group 0.000 claims description 6
- 208000028169 periodontal disease Diseases 0.000 claims description 6
- 230000036303 septic shock Effects 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 5
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims description 5
- 150000008575 L-amino acids Chemical class 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- 208000037803 restenosis Diseases 0.000 claims description 5
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 5
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 229910014585 C2-Ce Inorganic materials 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 4
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 125000006720 (C1-C6) alkyl (C6-C10) aryl group Chemical group 0.000 claims description 3
- 125000005035 acylthio group Chemical group 0.000 claims description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 230000000202 analgesic effect Effects 0.000 claims 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 2
- 206010039705 Scleritis Diseases 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- KEVSGIPPEHZMGV-OALZAMAHSA-N (2r,4r)-n-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(piperazine-1-carbonyl)piperidine-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1S(=O)(=O)N1[C@@H](C(=O)NO)C[C@H](C(=O)N2CCNCC2)CC1 KEVSGIPPEHZMGV-OALZAMAHSA-N 0.000 claims 1
- FCLQINRREQAAHO-MAUKXSAKSA-N (2r,4s)-1-[4-[(4-fluorophenyl)methoxy]phenyl]sulfonyl-n,4-dihydroxypiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1C[C@@H](O)CCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=C(F)C=C1 FCLQINRREQAAHO-MAUKXSAKSA-N 0.000 claims 1
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 71
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- 239000000243 solution Substances 0.000 description 44
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 43
- 235000011468 Albizia julibrissin Nutrition 0.000 description 41
- 241001070944 Mimosa Species 0.000 description 41
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 34
- 239000007787 solid Substances 0.000 description 33
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 28
- 125000006239 protecting group Chemical group 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 23
- 239000000706 filtrate Substances 0.000 description 21
- 150000002148 esters Chemical class 0.000 description 20
- 239000003112 inhibitor Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 16
- 108060005980 Collagenase Proteins 0.000 description 15
- 102000029816 Collagenase Human genes 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 229960002424 collagenase Drugs 0.000 description 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 14
- 239000012267 brine Substances 0.000 description 14
- 238000001914 filtration Methods 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- 238000007792 addition Methods 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 102100040247 Tumor necrosis factor Human genes 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 9
- 239000011593 sulfur Chemical group 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 102000004142 Trypsin Human genes 0.000 description 8
- 108090000631 Trypsin Proteins 0.000 description 8
- 239000012131 assay buffer Substances 0.000 description 8
- 239000011651 chromium Substances 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000006260 foam Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000012588 trypsin Substances 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 6
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 6
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 229910052744 lithium Inorganic materials 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000004677 Nylon Substances 0.000 description 5
- 239000000010 aprotic solvent Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 229920001778 nylon Polymers 0.000 description 5
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000007327 hydrogenolysis reaction Methods 0.000 description 4
- 150000002466 imines Chemical class 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000011777 magnesium Chemical group 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 150000002443 hydroxylamines Chemical class 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 3
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102100027995 Collagenase 3 Human genes 0.000 description 2
- 108050005238 Collagenase 3 Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000004210 ether based solvent Substances 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- DFFFQSWTAXMMBT-UHFFFAOYSA-N n-hydroxypiperidine-2-carboxamide Chemical compound ONC(=O)C1CCCCN1 DFFFQSWTAXMMBT-UHFFFAOYSA-N 0.000 description 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 108091007196 stromelysin Proteins 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- UKORJQFGYTXTJJ-HXUWFJFHSA-N (2r)-n-hydroxy-2-methyl-3-oxo-1-[4-(2-pyridin-4-ylethoxy)phenyl]sulfonylpiperidine-2-carboxamide Chemical compound C1CCC(=O)[C@](C)(C(=O)NO)N1S(=O)(=O)C(C=C1)=CC=C1OCCC1=CC=NC=C1 UKORJQFGYTXTJJ-HXUWFJFHSA-N 0.000 description 1
- ZJUWKHYEAIJQFV-RHSMWYFYSA-N (2r,4r)-2-(hydroxycarbamoyl)-1-[4-(pyridin-4-ylmethoxy)phenyl]sulfonylpiperidine-4-carboxylic acid Chemical compound ONC(=O)[C@H]1C[C@H](C(O)=O)CCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=NC=C1 ZJUWKHYEAIJQFV-RHSMWYFYSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- ZLBJQKXSLZFZSC-UHFFFAOYSA-N 1-(4-methoxyphenyl)sulfonylpiperidine Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1CCCCC1 ZLBJQKXSLZFZSC-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- DJDZQUUEISURMY-UHFFFAOYSA-N 1-aminopiperidine-2-carboxylic acid Chemical compound NN1CCCCC1C(O)=O DJDZQUUEISURMY-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- NCQJBPXXRXOIJD-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-naphthalen-2-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C(CC(O)=O)NC(=O)OC(C)(C)C)=CC=C21 NCQJBPXXRXOIJD-UHFFFAOYSA-N 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical group [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 238000005821 Claisen rearrangement reaction Methods 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical group [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 241000490229 Eucephalus Species 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- VCDNHBNNPCDBKV-DLOVCJGASA-N His-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N VCDNHBNNPCDBKV-DLOVCJGASA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 102100029692 Matrix metalloproteinase-21 Human genes 0.000 description 1
- 101710082411 Matrix metalloproteinase-21 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical group SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Chemical group 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Chemical group 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- CZFNISFYDPIDNM-UHFFFAOYSA-N n,n-dimethylformamide;oxolane Chemical compound CN(C)C=O.C1CCOC1 CZFNISFYDPIDNM-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- WZWGGYFEOBVNLA-UHFFFAOYSA-N sodium;dihydrate Chemical compound O.O.[Na] WZWGGYFEOBVNLA-UHFFFAOYSA-N 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
Description
<div class="application article clearfix" id="description">
<p class="printTableText" lang="en">WO 98/34918 <br><br>
PCT/TB98/00064 <br><br>
-1- <br><br>
5 <br><br>
ARYLSULFOMYL HYDROXAMIC ACID DERIVATIVES Background of the Invention The present invention relates to aryisutfonyl hydroxamie acid derivatives which are inhibitors of matrix metalloproteinases or the production of tumor necrosis factor 10 ■ (TNF) and as such are useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scisritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used 15 in combination therapy with standard non-steroidal anti-inflammatory drugs (hereinafter NSAICCS) and analgesics for the treatment of arthritis, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and alkaloids, such as vincristine, in the treatment of cancer. <br><br>
This invention also relates to a method of using such compounds in the 20 treatment of the above diseases in mammals, especially humans, and to pharmaceutical compositions useful therefor. <br><br>
There are a number of enzymes which effect the breakdown of structural proteins and which are structurally related metalioproteases. Matrix-degrading metalloproteinases, such as gelatinase, stromeiysin and coliagenase, are involved in 25 tissue matrix degradation (e.g. collagen collapse} and have been implicated in many pathological conditions involving abnormal connective tissue and basement membrane matrix metabolism, such as arthritis (e.g. osteoarthritis and rheumatoid arthritis), tissue ulceration (e.g. corneal, epidermal and gastric ulceration), abnormal wound healing, periodontal disease, bone disease (e.g. Pagefs disease and osteoporosis), tumor 30 metastasis or invasion, as well as HIV-infection (J. Leuk. Biol.. §£ (2): 244-248,1992). <br><br>
Tumor necrosis factor is recognized to be involved in many infectious and autoimmune diseases (W. Fiers, FEBS Letters. 1991. 285.199). Furthermore, it has been shown that TNF is the prime mediator of the inflammatory response seen in sepsis and septic shock (C.E. Spooner at al., Clinical Immunology and Immunopatholoav. 1992, 35 62S11). <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -3- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-2- <br><br>
Summarv of the invention The present invention relates to a compound of the formula R5 p6 <br><br>
R4 \ / R8 <br><br>
R' <br><br>
1/ \ <br><br>
%r > <br><br>
so; <br><br>
H <br><br>
Q <br><br>
or the pharmaceutically acceptable salt thereof, wherein the broken line represents an optional double bond; <br><br>
X is carbon, oxygen, sulfur, SO, S02 or nitrogen; <br><br>
Y is carbon, oxygen, sulfur, SO, SQ, or nitrogen; <br><br>
R\ R2, R3, R4 R5, R6, R7, R8 and R9 are selected from the group consisting of hydrogen, hydroxy, (CVCeJalkyI optionally substituted by one or two groups selected from (Ci-CeJalkylthio, (CVC^alkoxy, trifluoromethyl, halo, (C6-Cn0)aryl, (C2-CB)heteroaryl, (C6-C10)arylamino, (C6-C10)arylthio, (Ce-C10)aryloxy, (C2-C9)heteroarylamino, (C2-C9)heteroarylthio, (C2-C9)heteroaryloxy, (C6-C10)aryl(C6-C10)aryl, (C3-C8)cycloalkyl, hydroxy, piperazinyl, (CB-C^JaryKCi-CaJalkoxy, (C2-C9)heteroaryl(C1-C6)alkoxy, (C^CeJacylamino, (Cr C6)acylthio, (CVCeJacyloxy, (CVCeJalkylsulfinyl, (C6-C10)arylsulfinyl, (C^CeJalkylsulfonyl, (C6-C10)arylsulfonyl, amino, (CrC6)alkylamino or ((CrCeJalkyO^mino; (C2-C6)alkenyl, (C6-Cio)aryl(C2-C6)alkenyl, (C2-C9)heteroaryl(C2-C6)alkenyl, (C2-Ce)alkynyl, (C6-C10)aryl(C2-C6)alkynyl, (C2-C9)heteroaryl(C2-C6)alkynyl, (CVC^alkylamino, (Ct-C^alkylthio, (C,-C6)alkoxy, perfluoro(C1-C8)alkyl, (C6-C10)aryl, (C2-C9)heteroaryl, (C6-C10)arylamino, (C6-C10)arylthio, (C6-C10)aryloxy, (C2-C9)heteroarylamino, (C2-C9)heteroarylthio, (C2-C9)heteroaryloxy, (C3-C8)cycloalkyl, (CrCsJalkyKhydroxymethylene), piperidyl, (Cr C6)alkylpiperidyl, (CrCeJacylamino, (C^CeJacylthio, (CrCe)acfTtl«5U£5^0 a group of the formula <br><br>
OF N.Z. <br><br>
1 4 jul 2000 <br><br>
RCHFIVPn <br><br>
3J6836 <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
10 <br><br>
V <br><br>
<J>y 11 <br><br>
<ch2)„ <br><br>
» <br><br>
wherein n is 0 to 6; <br><br>
yisOorl; <br><br>
W is oxygen or >NR24; <br><br>
Z is -OR11, -NR24R11, azetidinyi, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl or a bridged diazabicycloalky! ring selected from the group consisting of <br><br>
15 <br><br>
20 <br><br>
,<ch2> <br><br>
<ch2> <br><br>
m <br><br>
(ch2) <br><br>
•n' <br><br>
I <br><br>
V <br><br>
(CHE)m cch2>r <br><br>
-H' <br><br>
I <br><br>
V <br><br>
25 <br><br>
30 <br><br>
. (chj),. <br><br>
SUBSTITUTE SHEET f'RULF 261 <br><br>
INTELLECTUAL PROPERTY OFFICE OF N.Z. <br><br>
1 4 jul 2000 received <br><br>
WO 98/34918 <br><br>
wherein r is 1, 2 or 3; <br><br>
mis1or2; <br><br>
pis0or1;and <br><br>
V is hydrogen, (Cf-CaJalkyl, (CrCgJalkyl^O)-, (C^Cg) alkoxy(OO)-, (Qr C10)aryl(G=O)-, (C6-C10)aryloxy(C=O)-, (Ce-C^aryKCrC^alkyKC^)-, (C6-C10)aryl-(C1-C6)alkoxy(C=0)-, or (CrC6)alkoxy(C=0)-0-; <br><br>
wherein each heterocyclic group (i.e., each Z cyclic group containing one or more heteroatoms) may optionally be independently substituted by one or two groups selected from hydroxy, (Q-CeJalkyl, (CrC6)alkoxy, (CrC10)acyl, (C1-C10)acyloxy, (C6-C10)aryl, (Cz-C9)heteroaryl, (C8-C10)aryl(CrC6)alkyl, (CVAOheteroaryKCVCeJalkyl, hydroxy(C1-C6)alkyl, (Cr CeJalkoxy^rCeJalkyl, (CrCeJacyloxyfCVCeJalkyl, (CrC6)alkylthio, (CrC6)alkylthio(CrC6)alkyl, (C6-C10)arylthio, (C6-C10)arylthio(C1-C6)alkyl, R12R13N-, R12R13NS02-, R12R13N(C=0)-, R12R13N(C=0)-(C1-C6)alkyl, R14S02-, R14S02NH-, R15(C=0)-[N(R12)]-, R180(C=0)-, or R160(C=0)-(CrC6)alkyl; <br><br>
wherein R10 is (^-CeJacylpiperazinyl, (C6-C10)arylpiperazinyl, (C2-C9)heteroarylpiperazinyl, (Q-CeJalkylpiperazinyl, (Ce-C^JaryKC^CeJalkylpiperazinyl, (C2-CgJheteroaryKCrCeJalkyipiperazinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidyl, (C,-C6)alkylpiperidyl, (C6-C10)arylpiperidyl, (C2-Ce)heteroarylpiperidyl, (C^CeJalkylpiperidyKC,-C6)alkyl, (C6-C10)arylpiperidyl(C1-C6)alkyl, (C2-C9)heteroaryl-piperidyl-(CrC6)alkyl or (Cr C6)acylpiperidyl; <br><br>
R11 is hydrogen, (C6-C10)aryl, (C2-C9)heteroaryl, (Ce-C^JaryKCrCaJalkyl, (Cj,-C9)heteroaryl(C1-C6)alkyl, (C1-C6)alkyl(C6-C10)aryl(C1-C6)alkyl, (Ci-CgJalkyKCj-CgJheteroaryKC,-Cs)alkyl, 5-indanyl, -CHR170-(C=0)-R18 or -CH2(C=0)-NR19R20; <br><br>
R12 and R13 are each independently hydrogen, (C,-C6)aikyl, (C6-C10)aryl, (C2-C9)heteroaryl, (C6-C10)aryl(C1-C6)alkyi or (Cj-CgJheteroaryKCVCeJalkyl or R12 and R13 may be taken together with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or thiomorpholinyl ring; <br><br>
R14 is trifluoromethyl, (C,-Ce)alkylf (QrC10)aryl, (C2-C9)heteroaryl, (Ca-C^JaryKC,-C6)alkyl or ((^-CgJheteroaryKCrC^alkyl; <br><br>
R15 is hydrogen, (CVC^alkyl, (Q-C^alkoxy, (Ce-C10)aryl, (C2-C9)heteroaryl, (Cr CeJaryKC^CeJalkyKCa-C^JaryKCrCeJalkoxy or (Cj-C^JheteroaryKCrCeJalkyl; <br><br>
R18 is (C^CeJalkyl, (Ce-C10)aryl, (Cj-CgJheteroaryl, (CVC^aryKCVCejalkyl, 5-indanyl, - <br><br>
[CH(R17)]0-(C=0)-R18, -CH2(C=O)-NR19R20i or R^CKCrQJalkyl; lNltLLt(;TUAL PROPERTY OFFICE <br><br>
OF N.Z. <br><br>
1 4 jul 2000 RFf!Cl\/cn <br><br>
536836 <br><br>
WO 98/34918 PCT/IB98/00064 <br><br>
-5- <br><br>
R17 is hydrogen or (CrC^alkyl; <br><br>
R18 is (C^CeJalkyl, (CVC^alkoxy or (C6-C10)aryl; <br><br>
R18 and R20 are each independently hydrogen or (C,-Ce)alkyl or may be taken together with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or thiomopholinyl ring; <br><br>
R21 is H2N(CMR22)(C=OK <br><br>
R22 is the side chain of a natural D- or L-amino acid; <br><br>
R23 is hydrogen, (C,-C6)acylf (CVQalkyl, (Ce-CJaryKCrQOalkyl, ((VOOheteroaryKCr C6)alkyl or (C^-C^alkylsulfonyl; <br><br>
R24 wherever it occurs is independently hydrogen or (C,-C8)alkyl; <br><br>
or R1 and R2, or R3 and R4, or R5 and R6 may be taken together to form a carbonyl; <br><br>
or R1 and R2, or R3 and R4, or R5 and R8, or R7 and R8 may be taken together to form a (C3-C6)cycloalkyl, oxacyclohexyl, thiocyclohexyl, indanyl or tetralinyl ring or a group of the formula <br><br>
Q is (C-(-Cto)alkyl, (Cg-C^oJaryl, (Cg-C1o)aryloxy(C6-Cio)aryl, (Cg-C^o)aryl(Cg-Cio)aryl, (Cg-C10)aryl(C6-C10)aryl(CrC6)alkyl, (C6-C10)aryl(C1-C6)alkoxy(C1-C8)alkyl, (C6-C10)aryloxy(C2-C9)heteroaryl, (Cj-Cg)heteroaryl, (Ci-C8)alkyI(C8-Cig)aryl, (Ct-C8)alkoxy(Ca-Cfo)aryl, (C8-CioJaryKCrCsJalkoxy^a-CujJaryl, (C2-C0)heteroaryloxy(C6-C1o)aryl, (C^CeJalkyKCj-C9)heteroaryl, (C1-C6)alkoxy(C2-C9)heteroaryl, (C1-C9)heteroaryl(C1-C8)alkoxy(C6-C10)aryl, (C2-Ca)heteroaryloxy(C2-C9)heteroaryl, (C8-C10)aryloxy(C1-C8)alkyl, (C2-C9)heteroaryloxy(C1-C6)alkyl, (C1-C8)alkyl(C8-C10)aryloxy(C6-C10)aryl, (CrC6)alkyl(C2-C9)heteroaryloxy(C8-C10)aryl, (Ci-C6)alkyl(C8-C10)aryloxy(C2-C9)heteroaryl, (CrCeJalkoxyCCB-C^JaryloxyfCVCmJaryl, (Cr C6)alkoxy(C2-C9)heteroaryloxy(C6-C10)|ryl or (C1-C6)alkoxy(C8-C10)aryloxy(C2-C9)heteroaryl optionally substituted by fluoro, chloro, (C,-C6)alkyl, (CrCeJalkoxy or perfluoro(C1-C3)alkyl; <br><br>
with the proviso that when y is zero, Q is other than (Q-C10)aryl(C8-C10)aryl, (C,,-CmJaryKCrCaJalkoxy^B-C^Jaryl or (C1-C9)heteroaryl(C1-C6)alkoxy(C,-C10)aryl, and anyone of R1-R9 is a group of formula II then 2 must be substituted when defined as azetidinyl, <br><br>
pyrrolidinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindoliny tetrahydroquinolinyl. <br><br>
INTELLECTUAL PROPERTY OFFICE OF N.2 <br><br>
1 jul 2000 <br><br>
Dtrrciucn <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
tetrahydroisoquinolinyl, piperazinyl, (CVC^acylpiperazinyl, (C^C^alkylpiperazinyl, (CV C10)arylpiperazinyl, (C2-C9)heteroarylpiperazinyl or a bridged diazabicycloalkyl ring; <br><br>
with the proviso that when y is zero, Q is other than (Q-C10)aryl(C6-C10)aryl, (0,-C10)aryl(C1-C6)alkoxy(C6-C10)aryl or (^-CsJheteroaryKC^-CgJalkoxyfCVC^aryl, then at least one of R1, R2, R3, R4, R5, R6, R7, R8 and R9 must be defined as the group of formula II; <br><br>
with the proviso that when Q is (Q-CwJaryKCe-CwJaryl, (Ce-C^aryKC^C^alkoxyCCV C10)aryl or (C1-C9)heteroaryl(C1-C6)alkoxy(Ce-C10)aryl, then R1-R9 may be other than formula II but when R\ R2, R3, R4, R5, R6, R7, R8, and R9 are all defined by hydrogen or (Q-CeJalkyl, either X or Y is oxygen, sulfur, SO, -SQ- or nitrogen, or the broken line represents a double bond; with the proviso that R7 is other than hydrogen only when R? is other than hydrogen; <br><br>
with the proviso that R? is other than hydrogen only when R? is other than hydrogen; <br><br>
with the proviso that R3 is other than hydrogen only when R4 is other than hydrogen; <br><br>
with the proviso that R2 is other than hydrogen only when R1 is other than hydrogen; <br><br>
with the proviso that when R\ R2 and R9 are a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 2- or 6- positions of the ring; <br><br>
with the proviso that when X is nitrogen, R1 is not present; <br><br>
with the proviso that when X is oxygen, sulfur, SO, SQ or nitrogen and when one or more of the group consisting of R1, R2, R5 and R8, is a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 4- or 6- positions; <br><br>
with the proviso that when Y is oxygen, sulfur, SO, SQ or nitrogen and when one or more of the group consisting of R?, R4, R7 and R8, are independently a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 3- or 5- positions; <br><br>
with the proviso that when X is oxygen, sulfur, SO or SQ, R3 and R4 are not present; <br><br>
with the proviso that when y is 1 and W is NF?4 or oxygen, Z cannot be hydroxy; <br><br>
with the proviso that when Y is oxygen, sulfur, SO or SQ, R5 and R6 are not present; <br><br>
with the proviso that when Y is nitrogen, R3 is not present; <br><br>
with the proviso that when the broken line represents a double bond, Ft and R6 are not present; <br><br>
with the proviso that when R3 and R5 are independently a substituent comprising a heteroatom when the broken line represents a double bond, the heteroatom cannot be directly bonded to positions X and Y; <br><br>
with the proviso that when either the X or Y position is oxygen, sulfur, SO, SQ> or nitrogen, the other of X or Y is carbon; <br><br>
INTELLECTUAL PROPERTY OFFICE OF N.Z. <br><br>
1 4 JUL 2000 <br><br>
u o <br><br>
WO 98/34918 <br><br>
PCT/TB98/00064 <br><br>
-7- <br><br>
with the proviso that when X or Y is defined by a heteroatom, the broken line does not represent a double bond. <br><br>
The term "alky!*, as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or 5 combinations thereof. <br><br>
The term "alkoxy*, as used herein, indudes O-aikyl groups wherein 'alkyl* is defined above. <br><br>
The term 'aryl', as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as 10 phenyl or naphthyi, optionally substituted by 1 to 3 substituents independently selected from the group consisting of fluoro, chloro, cyano, nitro, trifluoromethyl, (C,-C9)alkoxy, (Ce-C,0)aryioxy, trifluoromethoxy, difluoromethoxy and (C,-C8)aikyt. <br><br>
The term 'heteroaryf*, as used herein, unless otherwise indicated, inciudes an organic radical derived from an aromatic heterocyclic compound by removal of one 15 hydrogen, such as pyridyi, furyl, pyroyi, thienyi, isothiazolyl, imidazolyl, benzimidazolyl, tetrazolyl, pyrazinyt, pyrimidyl, quinolyl, isoquinolyl, benzofuryl, isobenzofuryl, benzothienyl, pyrazolyl, indolyl, isoindolyt, purinyl, carbazolyl, isoxazolyl, thiazolyl, oxazolyl, benzthiazoiyl or benzoxazolyl, optionally substituted by 1 to 2 substituents independently selected from the group consisting of fluoro, chloro, trifluoromethyl, (Cr 20 Cs)alkoxy, (Ca-C10)aryioxy, trifluoromethoxy, difluoromethoxy and (C,-C„)alkyl. <br><br>
The term 'acyl', as used herein, unless otherwise indicated, includes a radical of the general formula RCO wherein R is alkyl, alkoxy (such as methyioxy carbonyl), aryl. arylalkyl or arylalkyloxy and the terms 'alkyl* or "aryl* are as defined above. <br><br>
The term 'acyioxy*, as used herein, inciudes O-acyl groups wherein 'acyl' is 25 defined above. <br><br>
The term 'D- or L-amino acid', as used herein, unless otherwise indicated, includes glycine, alanine, valine, leucine, isoleucine, phenylalanine, asparagine, glutamine, tryptophan, proline, serine, threonine, tyrosine, hydroxyproiine, cysteine, cystine, methionine, aspartic add, glutamic add, lysine, arginine or histidine. 30 The positions on the ring of formula I, as used herein, are defined as follows: <br><br>
INTELLECTUAL PROPERTY OFFICE OF N.Z. <br><br>
i * jul 2000 RECEIVED <br><br>
WO 98/34918 <br><br>
PCT/DB98/00064 <br><br>
-8- <br><br>
5 N <br><br>
4 <br><br>
Y. <br><br>
3 <br><br>
2 <br><br>
N' 1 <br><br>
The preferred conformation of the compound of formula I inciudes hydroxamic acid axially disposed in the 2-position. <br><br>
The compound of formula I may have chiral centers and therefore exist in different enantiomeric forms. This invention relates to all optical isomers and stereoisomers of the compounds of formula I and mixtures thereof. <br><br>
Preferred compounds of formula I include those wherein Y is carbon. <br><br>
Other preferred compounds of formula I include those wherein Q Is (C,-C9)alkoxy(C9-C,0)aryl. (C8-Cie)aryl(C,-C8)alkoxy(C8-C10)aryl, or (C8-C10)aryt(C,-C„)alkoxy(C, -C8)aikyl wherein each terminal aryl group is optionally substituted by fluoro. <br><br>
Other preferred compounds of formula I include those wherein RJ, R\ Ra, R7 and R* are hydrogen. <br><br>
More preferred compounds of formula I include those wherein Y is carbon; Q is (C, -CB)alkoxy(C9-C, 0)aryl, (C9-C, 0)aryl(C, -C8)alkoxy(C8-C, 0)aryl, or (C9-C10)aryl(C,-C8)alkoxy(C,-C8)alkyl. <br><br>
Specific preferred compounds of formula I include the following: <br><br>
{2E.4B)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxyiic acid; <br><br>
(2B,4S)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid methyl ester; <br><br>
(2B,4B)-1-[3-(4-Fluorophenoxy)-propane-1-suifonyl]-2-hydroxycarbamoyl-piperidine-4-carboxyiic acid; <br><br>
(2Rl4B)-1-[3-(4-Fluorophenoxy)-propane-1-sulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid methyl ester; <br><br>
(2Q,3§)-{1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidin-3-yi}-carbamic acid isopropyl ester; <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -10- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-9- <br><br>
3-{S)-4-(4,-Fluorobiphenyl-4-sutfonyl)-2,2-dimothyl-thiomorpholine-3-carboxylic acid hydroxyamide; <br><br>
3-(§)-4-[4-{4-Fluorobenzyloxy)benzenesuifonyl]-2,2-dimethyl-thiomorpholine-3-carboxytic acid hydroxyamide; <br><br>
(2B.4§)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-4-hydroxy-piperidine-2-carboxytic acid hydroxyamide; and <br><br>
(2R,4B)*1 -(4-Methoxybenzenesulfonyl)-4-(piperazine-1 -carbony1)-piperidine-2-carboxylic add hydroxyamide hydrochloride. <br><br>
Other compounds of the invention include: <br><br>
(3S)-4-[4-(2-Chloro-thiazol-5-ylmetboxy)-benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxyiic acid hydroxyamide; <br><br>
(3S)-2,2-Dimethyl-4-[4-(thiazol-5-ylmethoxy)-benzenesuJfonyi]-thiomorpholine-3-carboxylic add hydroxyamide; <br><br>
(3S)-2,2-Dimethyt-4-[4-{pyridin-4-yfmethoxy)-benz0nesuffonyl]«thlomorpholine-3-carboxylic add hydroxyamide; <br><br>
(3£)-4-{4-[2-{4-Fluorophenyl)-ethoxy]-benzenesulfonyl}-2,2-dimethyl-thlomorpholine-3-carboxylic add hydroxyamide; <br><br>
(3§)-2,2-Dimethyl-4-{4-{2-pyridin-4-yl-ethoxy)-benzenesutfonyll-thiomorpholine-3-carboxylic add hydroxyamide; <br><br>
(3S)-4-[4-(BenzothiazoU2-yimethoxy)-benzenesulfonyl]-2,2-dimethyl-thiomorphoiine-3-carboxyiic add hydroxyamide; <br><br>
(3§)-2,2-Dimethyl-4-[4-(5-trifluoromethyl-benzothiazol-2-ylmethoxy)-benzenesutfonyl]-thiomorphoHne-3-carboxylic acid hydroxyamide; <br><br>
(3S)-2,2-Dimethyi-4-[4-(1H-tetrazol-6-yimethoxy)-benzenesutfonyl]-thiomorphoKne-3-carboxylic add hydroxyamide; <br><br>
(2B,3S)-{1-[4-(2-Chloro-thiazol-5-ylmethoxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidin-3-yt}-carbamic add methyl ester; <br><br>
(2B,3§)-{2-Hydroxycarbamoyl-1-[4-(thiazol-5-ylmethoxy)-benzenesulfonyl]-piperidin-3-yl}-carbamic add methyl ester; <br><br>
(2B,3S)-{2-Hydroxycarbamoyl-1-[4-(pyridin-4-ylmethoxy)-benzenesulfonyl]-piperidin-3-yl}-carbamic add methyl ester; <br><br>
(2B,3§)-{1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidin-3-yl>-carbamic add methyl ester; <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -11- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-10- <br><br>
(2R, 3S)-( 1 -{4- [2-(4-Ruorophenyl)-«thoxy]-bonzenesutfonyl} -2-hydroxycarbamoyt-piperidin-3-yt)-carbamic acid methyl aster; <br><br>
(2B,3S)*{2-Hydroxycarbamoyl-1-[4-(2-pyridin-4-yl-ethoxy)-benzenesulfonyl]-piperidin-3-yl}-carbamic acid methyl ester; <br><br>
5 (2R.3SH 1 -[4-{Benzothlazol-2-ylmethoxy)-benzenesulfonyl]-2-hydroxycarbamoyl- <br><br>
piperidin-3-yl>-carbamic acid methyl ester; <br><br>
(2R,3£H2-Hydroxycarbamoyl-1-[4-{5-Wfluoromothyi-bertzothiazol-2-ylmethoxy)-benzer>esutfonyl}-piperidin-3-yl}-carbamic acid methyl ester; <br><br>
(2B,3S)-{2-Hydroxycarbamoyl-1-[4-{1hi-tetrazol-5-ylmethoxy)-benzenesijtfonyl]-10 piperidin-3-yl}-carbamic acid methyl ester; <br><br>
(2fl,3§)-1-[4-(2-Chloro-thlazol-6-ylmethoxy)-benzenesuifonyl]-3-hydroxy-piperidine-2-carboxylic acid hydroxyamide; <br><br>
(2R,3§)-3-Hydroxy-1-[4-(thiazol-5-ylmethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide; 15 (2B,3S)-3-Hydroxy-1-[4-(pyridin-4-ylmethoxy)-benzenesulfonyl]-piperidlne-2- <br><br>
carboxylic add hydroxyamide; <br><br>
(2Bi3§)-1-[4-(4-Ruorobenzyloxy)-benzenesulfonyl)-3-hydroxy-piperidine-2-carboxylic add hydroxyamide; <br><br>
(2R,3S}-1-{4-[2-(4-Ruorophenyl)-ethoxy]-benzenesulfonyl}-3-hydroxy-piperidine-20 2-carboxyiic add hydroxyamide; <br><br>
(2B,3S)-3-Hydroxy-1-l4-(2-pyridin-4-yl-ethoxy)-benzenesulfonyl]-piperidine-2-carboxylic add hydroxyamide; <br><br>
(2B,3S}-1-[4-(Benzothiazol-2-ylmethoxy)-benzenesulfonyi]-3-hydroxy-piperidine-2-carboxyiic add hydroxyamide; <br><br>
25 (2Bi3§)-3-Hydroxy-1-[4-(5-trifluoromethyl-benzothiazol-2-ylmethoxy)- <br><br>
benzenesuHonyi]-piperidine-2-carboxylic acid hydroxyamide; <br><br>
(2fi,3§)-3-Hydroxy-1 -[4-{1 H-tetrazol-5-ylmethoxy)-benzenesulfonyl]-piperidine-2-carboxylic add hydroxyamide; <br><br>
(2fl,3§)-1 -[4-{2-Chloro-ttiiazol-5-ytmethoxy)-benzenesuHbnyl]-3-hydroxy-3-methyl-30 piperidine-2-carboxylic acid hydroxyamide; <br><br>
(2B,3§)-3-Hydroxy-3-methyl-1-[4-(thiazol-5-ylmethoxy)-benzenesulfonyl]-piperid'me-2-carboxytic add hydroxyamide; <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -12- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-11- <br><br>
(2B.3§)-3-Hydroxy-3-methyl-1-[4-(pyridin-4-ylmethoxy)-benzenesuifonyl]-piperidine-2-carboxytic acid hydroxyamide; <br><br>
(2B.3S)-1 -[4-(4-Ruorobenzyioxy)-benzenesu)fonyi]-3-hydroxy-3^ri0thyl-pipefjdin8- <br><br>
2-carboxyiic add hydroxyamide; (2Q,3§)-1-{4-[2-(4-Fluorophenyl)-ethoxy]-benzenesuifonyl}-3-hydroxy-3-methyl- <br><br>
piperidine-2-carboxylic acid hydroxyamide; <br><br>
(2RJ3S)-3-Hydroxy-3-methyl-1-[4-{2-pyridin-4-yl-ethoxy)-benzenesuHonyl]-piperidine-2-carboxyiic add hydroxyamide; <br><br>
(2fi,3§)-1 -[4-(B®nzothiazol-2-yimethoxy)-benzenesulfonyl]-3-hydroxy-3-methyl-piperidine-2-carboxylic add hydroxyamide; <br><br>
(2B.3S)-3-Hydroxy-3-methyl-1-[4-{5-trifluoromethyi-benzothiazol-2-yimethoxy)-benzenesuifonyf]-piperidine-2-carboxyiic acid hydroxyamide; <br><br>
(2B.31)-3-Hydroxy-3-methyH -[4-(1 H-tetrazol-5-ytmethoxy)-benzenesulfonyl]-piperidine-2-carboxyiic add hydroxyamide; <br><br>
(3R)-4-[4-(2-Chioro-thiazol-5-ylmethoxy)-benzenesulfonyl]-2,2-dimethyl-morpholine-3-carboxylic add hydroxyamide; <br><br>
(3R)-2,2-Dimethyl-4-[4-(thiazol-5-ylmethoxy)-benzenesulfonyl]-morpholine-3-carboxyiic add hydroxyamide; <br><br>
(3B)-2,2-Dimethyl-4-[4-{pyridin-4«ylmethoxy)-benzenesulfonyl]-morpholine-3-carboxylic add hydroxyamide; <br><br>
(3B)-4-[4-(4-Fluorobenzyioxy)-benzenesuifonyll-2,2-dimethyl-morpholine-3-carboxyiic acid hydroxyamide; <br><br>
(3R)-4-{4-[2-(4-F1uorophenyl)-ethoxy]-benzenesuifonyl}-2,2-dimethyl-morpholine- <br><br>
3-carboxyiic add hydroxyamide; (3R)-2,2-Dimethyl-4-[4-(2-pyridln-4-yl-ethoxy)-benzenesulfonyl]-morpholine-3- <br><br>
carboxyiic add hydroxyamide; <br><br>
(3B)-4-[4-(Benzothiazol-2-yimethoxy}-b6nzenesutfony)3-2,2-dimethy}-morpholin6-3-carboxyiic add hydroxyamide; <br><br>
(3B)-2,2-Dimethyl-4-[4-(5-trifluoromethyi-ber»zothiazol-2-ylmethoxy)-benzenesutfonyl3-morpholine-3-carboxyiic add hydroxyamide; <br><br>
(3B}-22-DimethyM-[4-{1H-tetrazol-5-ylmethoxy)-benzenesulfonyl]-morphoiine-3-carboxyiic add hydroxyamide; <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -13- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-12- <br><br>
(2E>4BJ-1-[4-(2-Chloro-thiazol-5-ylmethoxy)-benzenesulfonyil-2-hydroxycarb&moyl-piperidin»4-cart>oxyiic acid; <br><br>
(2B,4S)-2-Hydroxyearbamoyl-1-[4-(thlazol-5-ylmathoxy)-benzone8u!fonylJ-piperidin®-4-carboxylic add; <br><br>
(2R,4R)-2-Hydroxycarbamoyl-1-[4-(pyridin-4-ylmethoxy)-benzenesulfonyl]-piperidine-4-carboxylic add; <br><br>
(2Q,4^-1-{4-{2-(4-FkJorophenyi)-«ithoxy]-b0nzenesuifonyi}-2-hydroxycarbainoyl-piperidine-4-carboxy)io add; <br><br>
(2R,4R)-2-Hydroxycarbamoyl-1-[4-(2-pyridin-4-yl-ethoxy)-benzenesulfonyl]-piperidine-4-carboxytic add; <br><br>
(2R,4R}-1-[4-{Benzothiazol-2-yimethoxy)-benzenesLiffonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic add; <br><br>
(2{3,4R)-2-Hydroxycarbamoyl-1-[4-{5-trifluoromethyi-benzothiazol-2-ylmethoxy)-benzenesulfonyi]-piperidine-4-carboxylic add; <br><br>
(2B,4B)-2-Hydroxycarbamoyl-1-[4-(1H-tetrazol-B-ylmethoxy)-benzene8uJfonyl]-piperidine-4-carboxylic acid; <br><br>
(3f^-4-[4-{2-Chloro-thiazol-5-ytmethoxy)-benzanesulfonyl]-3-methyl-morphofine-3-carboxyiic add hydroxyamide; <br><br>
(3B)-3-M«thyl-4-[4-^hiazol-5-ylmethoxy)-benzariesuifonyf]-morpholine-3-cart>oxyilc add hydroxyamide; <br><br>
(3R)-^MathyM-[4-(pyridirv4-ytmerthoxy)-benzenesulfony1]-morpholin&-3-carboxylic add hydroxyamide; <br><br>
(3R)-4-[4-(4-Ruoroberizyloxy)-b»nzen«sulfony1]-3-m0thyi-morpholine-3-carboxyiic acid hydroxyamide; <br><br>
(3@H-{4-[2-(4-Ruorophenyi)-ethoxy]-benzenesuffonyl}-3-methyi-morphoiine-3-carboxyiic add hydroxyamide; <br><br>
(3R)-3-Methyl-4-[4-{2-pyridin-4-yl-ethoxy)-benzenesulfonyl]-morpholine-3-carboxyiic add hydroxyamide; <br><br>
(3R)-4-[4-{Benzothiazol-2-yimethoxy)-benzenesulfonyl]-3-methyt-morpholine-3-carboxylic add hydroxyamide; <br><br>
(3Q)-3-M«thyl-4-[4-{5-trifluoromethyl-benzothiazol-2-yfrnethoxy)-benzenesutfony)]-morphofine-3-carboxyiic acid hydroxyamide; <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -14- <br><br>
WO 98/34918 <br><br>
PCT/1B98/00064 <br><br>
-13- <br><br>
(30)-3-Methyl-4-[4-{1H-tetrazol-5-ylmethoxy)-benzenesuifonyl]-morpholine-3-carboxyiic acid hydroxyamide; <br><br>
(2B)-1*[4-(2-Chloro-thiazol-5-ylmethoxy)-benzenesulfonyl]-2-methyI-3-oxo-piperidine-2-carboxyiic acid hydroxyamide; <br><br>
5 (2B)-2-Methyt-3-oxo-1 -[4-(thiazol-6-ylmethoxy)-benzenesulfonyl]-piperidine-2- <br><br>
carboxyiic add hydroxyamide; <br><br>
(2B)-2-Methyl-3-oxo-1-[4-(pyridin-4-ylmethoxy)-ber»zenesulfonyl]-piperidine-2-carboxyiic acid hydroxyamide; <br><br>
(2B)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyi]-2-methyl-3-oxo-piperidine-2-10 carboxyiic add hydroxyamide; <br><br>
(2R)-1 -{4-[2-(4-Fluorophenyi)-ethoxy]-bflnzenesu|{onyl}-2-methy1-3-oxo-piperidjne-2-carboxylic add hydroxyamide; <br><br>
(2R)-2-Methyl-3-oxo-1-[4-(2-pyridin-4-yl-ethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide; 15 (2B)-1-[4-(Benzothiazol-2-ylmethoxy)-benzenesulfonyl]-2-methy1-3-oxo-pipericfine- <br><br>
2-carboxylic add hydroxyamide; <br><br>
(2B)-2-Methyl-3-oxo-1-[4-(5-trifluoromethyl-benzothlazol-2-ylmethoxy)-benzenesuifonyi]-piperidine-2-carboxylic acid hydroxyamide; <br><br>
(2fl)-2-Methyl-3-oxo-1 tl-tetrazol-6-ylmethoxy)-benzsnesui{ony1]-pipeodjne-2-20 carboxyiic add hydroxyamide; <br><br>
(2B,4§)-1-(4-Benzyloxy-benzenesulfonyl)-4-butylaminomethyl-4-hydroxy-piperidine-2-carboxylic add hydroxyamide; <br><br>
(2R>4§)-4-Butylaminomethyl-1-[4-{4-fluorobenzyloxy)-benzenesuHbnyl]-4-hydroxy-piperidine-2-carboxytic add hydroxyamide; <br><br>
25 (2Q,4SH-Benzylamino-1 -(4-benzyioxy-benzenesulfonyi)-piperidine-2-carboxylic add hydroxyamide; <br><br>
(2R,4S)-4-Benzy1amino-1-[4-(4-fiuorobenzyioxy)-benzenesulfony1]-piperidine-2-carboxylic add hydroxyamide; <br><br>
(20)-1 -[4-<4-Ruorobenzytoxy)-benzenesulfonyfl-4-oxo-piperidine-2-carboxyiic acid 30 hydroxyamide; <br><br>
(2B,40)-1-(4-Benzyioxy-benzenesulfonyl)-4-hydroxy-piperidine-2-carboxylicadd hydroxyamide; <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -15- <br><br>
WO 98/34918 <br><br>
PCT/IB98/Q0064 <br><br>
-14- <br><br>
(2fi,4B)-1-[4-(4-Fluorobenzyloxy)*b«nzenesulfonyl]-4-hydroxy-piperidlne-2-carboxytic acid hydroxyamide; <br><br>
(2R)-1-[4-{4-Ruorobenzytoxy)-b9nzenesutfonyl]-4-methyi-piperazins-2-cart>oxylic acid hydroxyamide; <br><br>
S (2B.5§)-1 -[4-(4-Fluorobenzyloxy)-benzenesuifonyl]-5-hydroxy-piperidine-2- <br><br>
carboxyiie acid hydroxyamide; <br><br>
(2B,5§)-1-(4-Benzytoxy-benzenesu)fonyl)-5-hydroxy-piperidin»-2-carboxyttcacid hydroxyamide; <br><br>
(2R,5B)-1-(4-Benzyioxy-benzenesutfony1)-5-hydroxy-piperidine-2-carboxy1icacid 10 hydroxyamide; <br><br>
(2B,5R)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-5-hydroxy-piperidine-2-carboxylic acid hydroxyamide; <br><br>
(25,3§}-1-(4-Benzyioxy-benzenesuifonyl)-3-hydroxy-piperidine-2-carboxylieadd hydroxyamide; <br><br>
15 (2Q,4S)-1 -{4-Benzyloxy-ben2enesu}fony))-4-hydroxy-piperidine-2-carboxylicacid hydroxyamide; <br><br>
(2fi,4S)-1-[4-(4-Fiuorobenzyloxy)-benzenesulfonyl]-4-hydroxy-piperidine-2-carboxytic add hydroxyamide; <br><br>
1 -(4-8utoxy-benzenesuH6nyl)-3-(morphoHne-4-carbonyl)-piper1dine-2-cart>oxyiic 20 acid hydroxyamide; <br><br>
1 -[4-{4-Fiuoro-benzyioxy)-benzenesutfonyf)-3-{morpholine-4-carbonyl)-piperidine-2-carboxyiic acid hydroxyamide; <br><br>
1 -[3-(Fluoro-benzyloxy)-propane-1 -sutfonyf]-3-(morpholinG-4-carbony1}-piperidjne-2-carboxyiic acid hydroxymide; 25 1 •(4-Butoxy-benzsnesuifonyi)-3-(pyrrolidine-1 -carbonyl)-piperidine-2-carboxyiic acid hydroxyamide; <br><br>
1 -[4-(4-Ruoro-benzytoxy)-berizene8utfonyi}-3-<pyiToBdine-1 -carbonyt)-pipefkfme-2-carboxyiic acid hydroxyamide; <br><br>
1 - [3-(4-Fluoro-benzy loxy)-propane-1 -suif onyl)-3-(pyrrolidine-1 -carbonyl)-30 piperidine-2-carboxyiic acid hydroxyamide; and <br><br>
1-[4-(4-Fiuoro-banzyioxy)-benzenesulfonyi]-2-hydroxycarbamoyl-piperidine-4-carboxylic add. <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -16- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-15- <br><br>
The present invention also relates to a pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, cancer, synergy with cytotoxic anticancer agents, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, sderitis, in combination with standard 5 NSAID-S and analgesics and other diseases characterized by matrix metailoproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) or (b) the inhibition of matrix metalloproteinases or the production of tumor necrosis factor (TNF) in a mammal, Including a human, comprising an amount of a compound of formula I or a pharmaceuticaily acceptable salt thereof 10 effective in such treatments and a pharmaceuticaily acceptable carrier. <br><br>
The present invention also relates to a method for the inhibition of (a) matrix metalloproteinases or (b) the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of formula I or a pharmaceuticaily acceptable salt thereof. 15 The present invention also relates to a method for treating a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, sderitis, compounds of formula I may be used in combination with standard NSAICS and analgesics and in combination with cytotoxic anticancer agents, and other diseases characterized by 20 matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an amount of a compound of formula I or a pharmaceuticaily acceptable salt thereof effective in treating such a condition. <br><br>
25 <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -17- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-16- <br><br>
Detaited Description of the Invention The following reaction Schemes illustrate the preparation of the compounds of the present invention. Unless otherwise indicated R', R2, R3, R4, Rs, R", R7, R*. R', n and At in the reaction Schemes and the discussion that fbiiow are delined as above. 5 Preparation 1 <br><br>
10 <br><br>
R IT™. <br><br>
15 <br><br>
20 <br><br>
xvi <br><br>
25 <br><br>
"If <br><br>
„AL°h <br><br>
R1' <br><br>
co.r" <br><br>
A, <br><br>
8 I <br><br>
s02q vi <br><br>
30 <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -18- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
10 <br><br>
-17-Preoaration 2 <br><br>
h nh2 <br><br>
V <br><br>
C0,R25 <br><br>
xviii cho c02r25 <br><br>
so2q xvii <br><br>
20 12 <br><br>
vi <br><br>
25 <br><br>
30 <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -19- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
10 <br><br>
15 <br><br>
20 <br><br>
-18- <br><br>
Sehemo 1 <br><br>
3Xoh <br><br>
COpR <br><br>
25 <br><br>
SOpQ <br><br>
VI <br><br>
NHOH <br><br>
SOgQ III <br><br>
Xy <br><br>
«Spir^r9 <br><br>
R'ka <br><br>
25 <br><br>
30 <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -20- <br><br>
WO 98/34918 <br><br>
PCMB98/00064 <br><br>
-19- <br><br>
S9h«w3 <br><br>
r26 <br><br>
Cl <br><br>
^N *C00H s02q ix <br><br>
10 <br><br>
1 <br><br>
h <br><br>
15 <br><br>
s02q <br><br>
20 <br><br>
viii <br><br>
2 <br><br>
25 <br><br>
30 <br><br>
s02q vii <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -21- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
*20- <br><br>
Scheme 3 <br><br>
h2n h02c > <br><br>
Ri^N^V I o s02q xii or <br><br>
25 <br><br>
10 <br><br>
15 <br><br>
H <br><br>
OR25 <br><br>
I o so2a xi <br><br>
20 <br><br>
25 <br><br>
H <br><br>
NHOH <br><br>
30 <br><br>
so2a x <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -22- <br><br>
wo 98/34918 <br><br>
pct/ib98/00064 <br><br>
-21- <br><br>
10 <br><br>
Scheme 4 R' 06 _8 <br><br>
R4 \ ** / <br><br>
V M *£> <br><br>
R | tOOH R28 <br><br>
XXI I 1 <br><br>
15 <br><br>
J?V <br><br>
I <br><br>
R4 \ , <br><br>
^ Y I R H 'COOH <br><br>
20 <br><br>
XXI <br><br>
b <br><br>
25 <br><br>
30 <br><br>
R'r« <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -23- <br><br>
WO 98/34918 PCT/IB98/00064 <br><br>
-22- <br><br>
10 <br><br>
15 <br><br>
20 <br><br>
25 <br><br>
SehemB 4 eontlnuad XX <br><br>
R8 <br><br>
vv/ <br><br>
%00H <br><br>
R5 <br><br>
R« v /V <br><br>
% v # <br><br>
Rl T^N^HOH <br><br>
■ r <br><br>
0 <br><br>
S0eQ <br><br>
30 <br><br>
XIII <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -24- <br><br>
WO 98/34918 <br><br>
PCMB98/00064 <br><br>
-23- <br><br>
Scheme 5 R« l"/ <br><br>
-J-A) fTA* ,0 <br><br>
R I ..tOOR'0 Re <br><br>
10 <br><br>
15 <br><br>
20 <br><br>
25 <br><br>
XXV t 1 <br><br>
R31 <br><br>
_R* <br><br>
R \ g <br><br>
XXV <br><br>
R31 D® <br><br>
sfe. <br><br>
30 <br><br>
XX [V <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -25- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-24- <br><br>
Scheme 5 continued XXIV <br><br>
10 <br><br>
Rn <br><br>
«V J. / <br><br>
J t00R,# S0tQ <br><br>
XXIII <br><br>
15 <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -26- <br><br>
WO 98/34918 <br><br>
PCMB98/00064 <br><br>
-25- <br><br>
Preparation 1 refers to the preparation of intermediates of the formula VI. Compounds of the formula VI are converted to compounds of the formula I according to the methods of Scheme 1. The starting materials of formula XVI can be prepared according to methods well known to those of ordinary skill in the art. <br><br>
5 In reaction 1 of Preparation i, the compound of formula XV! is converted to the corresponding hydroxy ester compound of formula VI by first reacting XVI with an aryisulfonylhaiide in the presence of tiiethyt amine and an aprotic solvent, such as methylene chloride, tetrahydrofuran or dioxane, at a temperature between about 20° C to about 30° C, preferably at room temperature. The compound so formed is further 10 reacted with a compound of the formula <br><br>
R9 COaR25 <br><br>
T <br><br>
Br <br><br>
15 wherein R28 is carbobenzyioxy, (C,-C8)alkyl, benzyl, ally! or tert-butyi, in the presence of sodium hexamethyldisilazane and a tetrahydrofuran-dimethyiformamide solvent mixture at a temperature between about -20°C to about 20°C, preferably about 0°C, to form the hydroxy ester compound of formula VI. <br><br>
Preparation 2 refers to an alternate method of preparing compounds of the 20 formula VI. The starting materials of formula XVIII can be prepared according to methods well known to those of ordinary skill in the art. In reaction 1 of Preparation 2, the amine compound of formula XVIII, wherein RM is as defined above, is converted to the corresponding arylsulfonyi amine compound of formula XVII by (1) reacting XVIII with an aryisulfonylhaiide in the presence of triethyiamine and an aprotic solvent, such 25 as methylene chloride, tetrahydrofuran, or dioxane, at a temperature between about 20°C to about 30°C, preferably at room temperature, (2) reacting the compound so formed with a compound of the formula <br><br>
30 <br><br>
in the presence of sodium hexamethyidisiiazane and a tetrahydrofuran-dimethylformamide solvent mixture at a temperature between about -20 °C to about 204C, preferably about 0°C, and (3) further reacting the compound so formed with ozone in a methylene chioride-methanol solution at a temperature between about -90°C <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -27- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-26- <br><br>
to about -70°C, preferably about -78°C. The unstable ozonlde compound so formed is then reacted with triphenylphosphine to form the aryisulfonyf amine compound formula XVII. In Reaction 2 of Preparation g, the arylsulfonyl amine compound of formula XVII is converted to the corresponding hydroxy ester compound of formula VI 5 by reacting XVII with a compound of the formula <br><br>
10 wherein W is lithium, magnesium, copper or chromium. <br><br>
Scheme 1 refers to the preparation of compounds of the formula II, which are compounds of the formula I, wherein X and Y are carbon; R4, R6 and R7 are hydrogen; and the dashed line between X and Y Is absent In reaction 1 of Scheme J, the compound of formula VI, wherein the R* protecting group is carbobenzyioxy, (C,-Ce) 15 alkyl, benzyl, ally! or tert-butyi, is converted to the corresponding morpholinone compound of formula V by lactonizaiion and subsequent Claisen rearrangement of the compound of formula VI. The reaction is facilitated by the removal of the RM protecting group from the compound of formula VI and is carried out under conditions appropriate for that particular R" protecting group in use. Such conditions include: (a) treatment 20 with hydrogen and a hydrogsnation catalyst, such as 10% palladium on carbon, where R28 is carbobenzyioxy, (b) saponification where R28 is lower alkyl, (c) hydrogenolysis where R25 Is benzyl, (d) treatment with a strong acid, such as trifluoroacetic add or hydrochloric add, where R* is tert-butyi, or (e) treatment with tributyitinhydride and acetic add in the presence of catalytic bis(triphenyiphosphine) palladium (II) chloride 25 where R2® is aUyi. <br><br>
In reaction 2 of Scheme i, the morpholinone compound of formula V is converted to the carboxyiic add compound of formula IV by reacting V with lithium hexamethyldisiiazane in an aprotic solvent, such as tstrahydrofuran, at a temperature between about -90°C to about -70°C, preferably about -78°C. Trimethylsilyl chloride 30 is then added to the reaction mixture and the solvent, tetrahydrofuran, is removed in vacuo and replaced with toluene. The resuling reaction mixture is heated to a temperature between about 100°C to about 120°C, preferably about 110°C, and treated with hydrochloric acid to form the carboxyiic add compound of formula IV. <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -28 <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-27- <br><br>
ln reaction 3 of Scheme i, the carboxyiic acid compound of formula IV is converted to the corresponding hydroxamic acid compound of formula III by treating IV with 1 -(3-dimethyiaminopropyl)-3-«thyicart>odiimide and 1-hydroxybenztriazole in a polar solvent, such as dimethyiformamide, followed by the addition of hydroxytamine 5 to the reaction mixture after a time period between about 15 minutes to about 1 hour, preferably about 30 minutes. The hydroxylamine is preferably generated }q from a salt form, such as hydroxylamine hydrochloride, in the presence of a base, such as N-methylmorphoiine. Alternatively, a protected derivative of hydroxylamine or its salt form, where the hydroxy! group is protected as a tert-butyi, benzyl or ally! ether, may 10 be used in the presence of (benzotriazol-1 -yloxy)tris(dimethyiamino) phosphonium hexafluorphosphate and a base, such as N-methyimorpholine. Removal of the hydroxylamine protecting group is carried out by hydrogenolysls for a benzyl protecting group or treatment with a strong acid, such as trifluoroacetic add, for a tert-butyi protecting group. The ally! protecting group may be removed by treatment with 15 tributyltinhydride and acetic add in the presence of catalytic bis(triphenyiphosphine) palladium (II) chloride. N,0-bls(4-methoxybenzyi)hydroxyiamine may also be used as the protected hydroxylamine derivative where deprotection is achieved using a mixture of methanesuHonic add and trifluoroacetic add. <br><br>
In reaction 4 of Scheme i, the hydroxamic acid compound of formula III is 20 converted, if desired, to the corresponding piperidine compound of formula II by treating III with hydrogen and a hydrogenation catayst, such a 10% palladium on carbon. <br><br>
Scheme 2 refers to the preparation of compounds of the formula VII, which are compound of the formula I wherein Y is nitrogen; X is carbon; R\ R2, R3, R\ R7 and R" 25 are hydrogen, and R' is absent. The starting materials of formula IX can be prepared according to methods well known to those of ordinary skill in the art. In reaction 1 of Scheme 2. the arylsuifonyipiperazine compound of formula IX, wherein RM Is carbobenzyioxy, benzyl or carbotertbutyloxy, is converted to the compound of formula VIII by reacting IX with a protected derivative of hydroxylamine of the formula 30 R,7ONH,«HCI <br><br>
wherein R27 is tertbutyl, benzyl or allyi, in the presence of dlcydohexyicarbodiimide, dimethylaminopyridine and an aprotic solvent, such as methylene chloride. The RM protecting group is chosen such that it may be selectively removed in the presence of an without loss of the R27 protecting group, therefore, RM cannot be the same as R27. <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -29- <br><br>
Wo 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-28- <br><br>
Removal of the R20 protecting group from the compound of formula IX is carried out under conditions appropriate for that particular RM protecting group in use. Such conditions include; (a) treatment with a hydrogen and a hydrogenation catalyst, such as 10% palladium on carbon, where RM is carbobenzyioxy, (b) hydrogenolysis where 5 R2# is benzyl or (c) treatment with a strong add, such as trifluoroacetic acid or hydrochloric acid where R2* is carbotertbutyioxy. <br><br>
In reaction 2 of Scheme 2. the compound of formula VIII is converted to the corresponding hydroxamic acid compound of formula VII, wherein R® is hydrogen or (C,-C8)aJkyl, by reacting, if desired, VIII with an aikylhalide when R8 is (C,-C8)aJkyi. 0 Subsequent removal of the R27 hydroxylamine protecting group is carried out by hydrogenolysis for a benzyl protecting group or treatment with a strong acid, such as trifluoroacetic add, for a tert-butyi protecting group. The aliyi protecting group may be removed by treatment with tributyltinhydride and acetic add in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride. <br><br>
5 Scheme 3 refers to the preparation of compounds of the formula X, which are compounds of the formula I wherein Y is nitrogen; X is carbon; R2, R7, R* and R* are hydrogen; R3 and R4 taken together are carbonyl; R8 is hydrogen, and R* is absent. In reaction 1 of Scheme 3, the aryisulfonyiamine compound of formula XII, wherein R28 is as defined above, is converted to the corresponding piperaane compound of formula 0 XI by reacting XII with a carbodiimide and a base, such as triethyiamine. The compound of formula XI is further reacted to give the hydroxamic add compound of formula X according to the procedure described above in reaction 3 of Scheme 1. <br><br>
Scheme 4 refers to the preparation of compounds of the formula XIII. The starting materials of formula XVIII can be prepared according to methods well known 5 to those of ordinary skill In the art. Compounds of the formula XIII are compounds of the formula i wherein X is carbon, and the dotted line between X and Y is absent tn reaction 1 of Scheme 4, removal of the R1* protecting group and subsequent reductive amination of the compound of formula XXII, wherein Y is oxygen, sulfur or carbon, to give the corresponding imine compound of formula XXI is carried out under conditions 10 appropriate for that particular R2* protecting group in use. Such conditions include those used above for removal of the R" protecting group In reaction 1 of Scheme £. <br><br>
In reaction 2 of Scheme 4, the imine compound of formula XXI Is converted to the corresponding piperidtne compound of formula XX by reacting XXI with a nudeophiie of the formula R2M wherein M Is lithium, magnesium haUde or cerium <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -30- <br><br>
WO 98/34918 <br><br>
PCMB98/00064 <br><br>
-29- <br><br>
halide. The reaction is carried out in ether solvents, such as diethyl ether or tetrahydrofuran, ait a temperature between about •78°C to about 0°C, preferably about -70°C. <br><br>
In reaction 3 of Scheme 4, the suttonation of the piperidine compound of 5 formula XX to given the corresponding aryisulfonytpiperidine compound of formula XIX is carried out by reacting XX with an aryisulfonylhaiide in the presence of triethyiamine and an aprotic solvent, such as methylene chloride, tetrahydrofuran or dioxane, at a temperature between about 20°C to about 30°C, preferably at room temperature. <br><br>
In reaction 4 of Schema 4, the arytsutfonyipiperidine compound of formula XIX 0 is converted to the hydroxamic acid compound of formula XIII according to the procedure described above in reaction 3 of Scheme 1. <br><br>
Scheme 5 refers to the preparation of compounds of the formula XIV, which are compounds of formula I wherein Y is nitrogen, X is carbon, the dotted line between X and Y is absent, R5 is hydrogen and R* is absent. In reaction 1 of Scheme §, the 5 compound of formula XXVI, wherein the RM and RS1 protecting groups are each independently selected from the group consisting of carbobenzyioxy, benzyl and carbotertbutyioxy and R30 is carbobenzyioxy, (C,-CB)alkyl, benzyl, ally! or tert-butyi, is converted to the corresponding imine compound of formula XXV by the removal of the R2* protecting group and subsequent reductive asnination of the compound of formula 0 XXVI. The R" protecting group is chosen such that it may be selectively removed in the presence of and without loss of the R3' protecting group. Removal of the R2* protecting group from the compound of formula XXVI is carried out under conditions appropriate for that particular R29 protecting group in use which will not affect the R31 protecting group. Such conditions include; (a) treatment with hydrogen and a !5 hydrogenation catalyst, such as 10% palladium on carbon, where R2* is carbobenzyioxy and R3' is tert-butyi, (b) saponification where R3* is (C,-C,)alkyi and R3' is tert-butyi, (c) hydrogenolysis where R2* is benzyl and R3> is (C,-C8) alkyl or tert-butyi, (d) treatment with a strong acid such as trifluoroacetic acid or hydrochloric acid where R2* is tert-butyi and R31 is (C,-Cfl)alkyil benzyl or ally!, or (e) treatment with tributyltinhydride and acetic 10 acid in the presence of catalytic bis(triphenyiphosphine) palladium (II) chloride where R2* is ally! and R11 is (C,-C,)alkyl, benzyl or tert-butyi. The R30 protective group may be selected such that it is removed in the same reaction step as the R2* protecting group. <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -31 <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-30- <br><br>
ln reaction 2 of Scheme jg, the imine compound of formula XXV is converted to the corresponding compound of formula XXIV by reacting XXV with a nudeophile of the formula R2M wherein M is lithium, magnesium haiide or calcium halide. The reaction is carried out in ether solvents, such as diethyl ether or tetrahydrofuran, at a 5 temperature between about -78°C to about 0°C, preferably about -70°C. <br><br>
In reaction 3 of Scheme §, the suHonation of the piperidine compound of formula XXIV to give the corresponding aryisutfonyipiperidine compound of formula III is carried out according to the procedure described above in reaction 3 of Scheme 4. <br><br>
In reaction 4 of Scheme §, the aryisutfonyipiperidine compound of formula XXIII 10 is converted to the hydroxamic add compound of formula XIV by (1) removing the R*°, if needed, and R" protecting groups from XXIII followed by (2) reacting XXIII according to the procedure described above in reaction 3 of Scheme 1. Removal of the RJ0 and RJ1 protecting groups from the compound of formula XXIII is carried out under conditions appropriate for that particular R*° and R" protecting group in use. Such 15 conditions include those used above for removal of the R26 protecting group in reaction 1 of Scheme 1. <br><br>
Pharmaceuticaily acceptable salts of the addle compounds of the invention are salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, caldum, magnesium, as well as ammonium 20 slats, such as ammonium, trimethyi-ammonium, diethylammonium, and tris-(hydroxymethyi)-methyiammonium salts. <br><br>
Similarly acid addition salts, such as of mineral acids, organic carboxyiic and organic sulfonic acids e.g. hydrochloric add, methanesulfonic add, maleic add, are also possible provided a basic group, such as pyridyl, constitutes part of the structure. 25 The ability of the compounds of formula I or their pharmaceuticaily acceptable salts (the compounds of the invention) to inhibit matrix metalloproteinases or the production of tumor necrosis factor (TNF) and, consequently, demonstrate their effectiveness for treating diseases characterized by matrix metalloproteinase or the production of tumor necrosis factor is shown by the following iQ vitro assay tests. <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -32 <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-31-Pip|(?qi9?J <br><br>
Inhibition of Human CoHaaenage fMMP-H Human recombinant collagenase is activated with trypsin using the following ratio: 10 fjg trypsin per 100 jjq of collagenase. The trypsin and collagenase are 5 incubated at room temperature for 10 minutes then a five fold excess (50 /*g/10 fig trypsin) of soybean trypsin inhibitor is added. <br><br>
10 mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted using the following Scheme: <br><br>
10mM > 120//M > 12//M > 1.2//M > 0.12 <br><br>
10 Twenty-five microliters of each concentration is then added in triplicate to appropriate wells of a 96 well microfluor plate. The final concentration of inhibitor will be a 1:4 dilution after addition of enzyme and substrate. Positive controls (enzyme, no inhibitor) are set up in wells D1-D6 and blanks (no enzyme, no inhibitors) are set in wells 07-012. <br><br>
16 Collagenase is diluted to 400ng/ml and 25 (A is then added to appropriate wells of the microfluor plate. Final concentration of collagenase in the assay is 100 ng/mi. <br><br>
Substrate (DNP-Pro-Cha-Gly-Cyt(Me)-His-Alat-Lys(NMA)-NHz) is made as aS mM stock in dimethyl sulfoxide and then diluted to 20 /iM in assay buffer. The assay is Initiated by the addition of 50 jA substrate per well of the microfluor piate to give a final 20 concentration of 10 fM. <br><br>
Fluorescence readings (360 nM excitation, 460 nm emission) were taken at time 0 and then at 20 minute intervals. The assay is conducted at room temperature with a typical assay time of 3 hours. <br><br>
Fluorescence vs time is then plotted for both the blank and collagenase 25 containing samples (data from triplicate determinations is averaged). A time point that provides a good signal (the blank) and that is on a linear part of the curve (usually around 120 minutes) is chosen to determine ICM values. The zero time is used as a blank for each compound at each concentration and these values are subtracted from the 120 minute data. Data is plotted as inhibitor concentration vs % control (inhibitor 30 fluorescence divided by fluorescence of collagenase alone x 100). IC^'s are determined from the concentration of inhibitor that gives a signal that is 50% of the control. <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -33- <br><br>
Wo 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-32- <br><br>
If IC,0's are reported to be <0.03 //M then the inhibitors are assayed at concentrations of 0.3 (jM, 0.03 fjM, 0.03 pM and 0.003 pM. <br><br>
Inhibition of Qelatinase (MMP-21 <br><br>
Inhibition of getatinase activity is assayed using the Dnp-Pro-Cha-Giy-Cys(Me)-5 His-Ala-Lys(NMA)-NH2 substrate (10 pM) under the same conditions as inhibition of human collagenase (MMP-1). <br><br>
72kD gelaiinase is activated with 1 mM APMA (p-aminophenyt mercuric acetate) for 15 hours at 4°C and is diluted to give a final concentration in the assay of 100 mg/ml. Inhibitors are diluted as for inhibition of human collagenase (MMP-1) to give 0 final concentrations in the assay of 30 f/M, 3 f/M, 0.3 /jM and 0.03 /jM. Each concentration is done in triplicate. <br><br>
Fluorescence readings (360 nm excitation, 460 emission) are taken at time zero and then at 20 minutes intervals for 4 hours. <br><br>
ICjo's are determined as per inhibition of human collagenase (MMP-1). If ICgo's 5 are reported to be less than 0.03 /jM, then the inhibitors are assayed at final concentrations of 0.3 pM, 0.03 pM, 0.003 pM and 0.003 //M. <br><br>
inhibition of Stromeivsln Activity (MMP-3) <br><br>
Inhibition of stromeiysin activity is based on a modified spectrophotometric assay described by Weingarten and Feder (Weingarten, H. and Feder, J., !0 Spectrophotometric Assay for Vertebrate Collagenase, Anal. Biochem. 147. 437-440 (1985)). Hydrolysis of the thio peptolide substrate [Ac-Pro-Leu-Gly-SCH[CH2CH(CH3)j]CO-Leu-Qly-OC2H5] yields a mercaptan fragment that can be monitored in the presence of EBman's reagent. <br><br>
Human recombinant prostrometysin is activated with trypsin using a ratio of 1 pi !5 of a 10 mg/ml trypsin stock par 26 pg of stromelysin. The trypsin and stromeiysln are incubated at 37°C for 15 minutes followed by 10 fA of 10 mg/ml soybean trypsin inhibitor for 10 minutes at 37°C for 10 minutes at 37°C to quench trypsin activity. <br><br>
Assays are conducted in a total volume of 250 pi of assay buffer (200 mM sodium chloride, 50 mM MES, and 10 mM calcium chloride, pH 6.0) in 96-well microliter 10 plates. Activated stromelysin is diluted in assay buffer to 25 pg/ml. Ellman's reagent (3-Carboxy-4-nitrophenyl disulfide) is made as a 1M stock in dimethyl formamide and diluted to 5 mM in assay buffer with 50 (A per wefl yielding at 1 mM final concentration. <br><br>
10 mM stock solutions of inhibitors are made in dimethyl sulfoxide and diluted serially in assay buffer such that addition of 50 /jL to the appropriate wells yields final <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -34- <br><br>
WO 98/34918 <br><br>
FCMB98/00064 <br><br>
-33- <br><br>
concentrations of 3 pM, 0.3 pM, 0.003 pM, and 0.0003 pM. All conditions are completed in triplicate. <br><br>
A 300 mM dimethyl sulfoxide stock solution of the peptide substrate is diluted to 15 mM in assay buffer and the assay is initiated by addition of 50 pi to each well to 5 give a final concentration of 3 mM substrate. Blanks consist of the peptide substrate and Ellman's reagent without the enzyme. Product formation was monitored at 405 nm with a Molecular Devices UVmax plate reader. <br><br>
IC50 values were determined in the same manner as for collagenase. <br><br>
Inhibition of MMP-13 <br><br>
0 Human recombinant MMP-13 is activated with 2mM APMA (p-aminophenyl mercuric acetate) for 1.5 hours, at 37°C and is diluted to 400 mg/ml in assay buffer (50 mM Tris, pH 7.5,200 mM sodium chloride, 5mM calcium chloride, 20pM zinc chloride, 0.02% brij). Twenty-five mieroltters of diluted enzyme is added per well of a 96 weU microfluor plate. The enzyme is then diluted in a 1:4 ratio in the assay by the addition 5 of inhibitor and substrate to give a final concentration in the assay of 100 mg/ml. <br><br>
10 mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted in assay buffer as per the inhibitor dilution scheme for inhibition of human collagenase (MMP-1): Twenty-five microliters of each concentration is added in triplicate to the microfluor plate. The final concentrations in the assay are 30 pM, 3pM, !0 0.3 pM, and 0.03 pM. <br><br>
Substrate (Dnp-Pro-Cha-Gly-Cys(Me)-His-AJa-Lys(NMA)-NH2) is prepared as for inhibition of human collagenase (MMP-1) and 50 pi is added to each well to give a final assay concentration of 10 pM. Fluorescence readings (360 nM excitation; 450 emission) are taken at time 0 and every 5 minutes for 1 hour. <br><br>
!5 Positive controls consist of enzyme and substrate with no inhibitor and blanks consist of substrate only. <br><br>
IC50's are determined as per inhibition of human collagenase (MMP-1). If ICk's are reported to be less than 0.03 pM, inhibitors are then assayed at final concentrations of 0.3 pM. 0.03 pM, 0.003 pM and 0.0003 pM. >0 Inhibition of TNF Production <br><br>
The ability of the compounds or the pharmaceuticaily acceptable salts thereof to inhibit the production of TNF and, consequently, demonstrate their effectiveness for treating diseases involving the production of TNF is shown by the following jQ vitro assay: <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -35- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-34- <br><br>
Human mononudear ceils wars isolated from anti-coaguiated human blood using a one-step Ficoll-hypaque separation technique. (2) The mononuclear cells were washed three times in Hanks balanced salt solution (HBSS) with divalent cations and resuspended to a density of 2 x 10s /ml in HBSS containing 1% BSA. Differential 5 counts determined using the Abbott Cell Dyn 3500 analyzer indicated that monocytes ranged from 17 to 24% of the total cells In these preparations. <br><br>
180*/ of the cell suspension was allquoted into fiate bottom 96 well plates (Costar). Additions of compounds and LPS (100ng/ml final concentration) gave a final volume of 20Q/ul. All conditions were performed in triplicate. After a four hour 10 incubation at 37°C in an humidified C02 incubator, plates were removed and centrifuged (10 minutes at approximately 250 x g) and the supematants removed and assayed for TNFo using the R&D EUSA Kit <br><br>
For administration to mammals, including humans, for the inhibition of matrix metalloproteinases or the production of tumor necrosis factor (TNF), a variety of 15 conventional routes may be used including orally, parenteraliy and topically. In general, the compound of the invention will be administered orally or parenteraliy at dosages between about 0.1 and 25 mg/kg body weight of the subject to be treated per day, preferably from about 0.3 to 5 mg/kg. However, some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person 20 responsible for administration will, in any event, determine the appropriate dose for the individual subject. <br><br>
The compounds of the invention can be administered in a wide variety of different dosage forms. In general, the therapeutically effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 25 5.0% to about 70% by weight. <br><br>
For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicaJcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably com, potato or tapioca starch), alginic add and certain complex silicates, 30 together with granulation binders like polyvinylpyrrolidone, sucrose, gelation and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabiettlng purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as wed as high molecular weight <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -36 <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-35- <br><br>
polyethytene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene 5 glycol, glycerin and various Hke combinations thereof. In the case of animals, they are advantageously contained in an animal feed or drinking water in a concentration of 5-5000 ppm, preferably 25 to 500 ppm. <br><br>
For parenteral administration (intramuscular, intraperitoneal, subcutaneous and intravenous use) a sterile injectable solution of the active ingredient is usually prepared. 0 Solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably adjusted and buffered, preferably at a pH of greater than 8, if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable intravenous injection purposes. The oily solutions are suitable for intraarticular, 5 intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art. In the case of animals, compounds can be administered intramuscularly or subcutaneously at dosage levels of about 0.1 to 50 mg/kg/day, advantageously 0.2 to 10 mg/kg/day given in a single dose or up to !0 3 divided doses. <br><br>
The present invention is illustrated by the following examples, but it is not limited to the details thereof. <br><br>
EXAMPUS1 <br><br>
<2R. 4RW1 -(4-Msthoicv-benzenesuHonviy-4-(ptoerazine-1 «carbonvl V-pjperidine-2-!5 carboxvllc acid hvdroxvamide hydrochloride <br><br>
(a) To a stirred, cold (-78 °C) solution of (2g)-2-benzyloxycarbonyiamino-pentanedioic add 1-tert-butyi ester 5-methyl ester (5.6g, 15.9 mmoi), prepared as described in J. Org. Chem., §§. 1711-1721 (1990) and J. Med. Chem., 32,73-85 (1996), in 30 ml of tetrahydrofuran was added lithium bis(trimethyisilyl)amide (40 mL, 1 M in 10 tetrahydrofuran, 39.8 mmoi). The resulting mixture was stirred for 1 hour at-45 °C and then recooled to -78 °C. Ally! bromide (5.2 mL, 63.7 mmoi) was then added. After 2 hours the reaction was quenched by the addition of 1 M aqueous hydrogen chloride at -78 °C. The mixture was then extracted with diethyl ether. The combined ethereal <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -37- <br><br>
WO 98/34918 <br><br>
PCMB98/00064 <br><br>
-36- <br><br>
extracts were washed with brine and the mixture was dried over sodium sulfate. After filtration and concentration of the filtrate, the crude product was purified by silica gel chromatography (elution with 1:5 ethyl acetata/hexanes) to provide (2jB,4B)-4-allyl-2-benzyloxycarbonyiamino-pentanedioic acid 1-tert-butyi ester 5-methyi ester. <br><br>
5 (b) Ozone gas was bubbled through a stirred, cold (-78 °C) solution of (2B.4BM-allyt-2-benzyioxycarbonyiamino-pentanedioic acid 1-tert-butyi ester 5-methyl ester (5.0 g, 12.8 mmoi) in 100 mL of 10:1 methanol/methylene chloride, and 0.73 mL of acetic acid until a blue color persisted. Nitrogen gas was then bubbled through the solution until the blue color dissipated. The mixture was warmed to ambient temperature and 10 dimethyl sulfide (2.8 mL, 3.83 mmoi) was added. The mixture was stirred for 48 hours, diluted with methylene chloride, and washed with 10% aqueous sodium carbonate, brine, and the mixture was dried over sodium sulfate. Filtration and concentration of the filtrate provided (23,4§)-6-methoxy-piperidine-1,2,4-tricarboxyiic add 1 -benzyl ester 2-tert-butyi ester 4-methyi ester as a dear oil, which was used in the subsequent step 15 without purification. <br><br>
(c) A mixture of {23,4§}-6-methoxy-pip«idine-1,2,4-tricarboxyiic add 1 -benzyl ester 2-tert-butyl ester 4-methyi ester (4.85 g, 11.9 mmoi) and 10% palladium on carbon (600 mg) in 100 mL of ethanoi was shaken under a 45 psi atmosphere of hydrogen gas for 1.5 hours. The mixture was filtered through nylon and the filtrate was concentrated to <br><br>
20 provide (2R,4R)-piperidine-2,4-dicarboxyHc add 2-tert-butyl ester 4-methyi ester as Ught yellow oii, which was used in the subsequent step without further purification. <br><br>
(d) To a stirred, cold (0 °C) solution of (2B,4B)-piperidine-2,4-dicarboxyiic acid 2-tert-butyi ester 4-methyi ester (2.7 g, 11.1 mmoi) and triethylamine (4.6 mi, 33.3 mmoi) in 30 mL of methylene chloride was added 4-methoxy-benzenesuifonyl chloride (2.3 g, <br><br>
25 11.1 mmoi). The mixture was warmed to ambient temperature and stirred for 4 hours. The reaction was quenched by the addition of aqueous ammonium chloride and the mixture was extracted with ethyl acetate. The combined organic extracts were washed with brine, and the organic mixture was dried over sodium sulfate. After filtration and concentration of the filtrate, the resulting crude product was purified by silica gel 30 chromatography (elution with 3:8 ethyl acetate/hexanes) to provide (2Q,4R)-1-(4-methoxy-benzenesutfonyl)-piperidine-2,4-dicarboxyiic add 2-tert-butyi ester 4-methyi ester. <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -38- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-37- <br><br>
(e) To a stirred, cold (0 °C) solution of (2R.4BH -(4-methoxy-benzenesulfonyl)-piperidine-2,4-dicarboxy1ic acid 2-tert-butyl ester 4-methyl ester (4.4 g, 10.6 mmoi) in 30 mL of methylene chloride was added 10 mL of trifluoroacetic acid dropwise. The mixture was stirred for 1 hour at 0 °C and for 8 hours at ambient temperature. <br><br>
5 Concentration provided (2B,4B)-1-(4-methoxy-benzenesulfonyl)-piperidine-2,4-dicarboxytic acid 4-methyl ester, which was used in the subsequent step without purification. <br><br>
(f) To a stirred solution of (2B.4B)-1-(4-methoxy-benzenesuifonyl)-piperidine-2,4-dicarboxylic acid 4-methyl ester (4.4 g, 12.3 mmoi), O-benzythydroxylamine <br><br>
10 hydrochloride (2.15 g, 13.5 mmoi), and triethylamine (5.15 mL, 36.9 mmoi) was added benzotriazol-1 •yioxy-tris(dimethylamino)phosphonium hexafluorophosphate (6.0 g, 12.3 mmoi) at ambient temperature. The resulting mixture was stirred for 24 hours. The mixture was diluted with ethyl acetate and washed with 1 M aqueous hydrogen chloride, aqueous sodium bicarbonate, and brine. The organic mixture was dried over 15 magnesium sulfate, filtered, and the filtrate was concentrated. The crude residue was purified by silica gel chromatography (elution with 5% methanol in methytene chloride) to provide (2Bl4Q}-2-benzyloxycarbamoyl-1-{4-methoxy-benzenesulfonyl)-plperidine- <br><br>
4-carboxyiic acid methyl ester as a colorless solid. <br><br>
(g) To a stirred cold (0 ° C) solution of (2B,4R)-2-benzyioxycarbamoyM -(4-methoxy-20 benzenesuifonyl)-piperidine-4-carboxyiic acid methyl ester (4.0 g, 8.6 mmoi) in 10 mL <br><br>
of 9:1 methanol/water was added lithium hydroxide monohydrate (1.8 g, 43 mmoi). The mixture was stirred for 2 hours before Amberlite IR-120 resin (96 g) was added. After 15 minutes, the mixture was filtered and the filtrate was concentrated to give (2B,4E)-2-benzyloxycarbamoyl-1 -(4-methoxy-benzenesutfonyi)-piperidine-4-cart>oxyiicacjd,which 25 was used in the subsequent reaction without purification. <br><br>
(h) To a stirred solution of (2B,4fi)-2-benzyioxycarbamoyl-1 -(4-methoxy-benzenesulfony()-piperidine-4-carboxyiie add (500 mg, 1.11 mmoi), tert-butyloxycarbonyl piperazine (226 mg, 1.21 mmoi), and triethylamine (0.47 mL, 3.33 mmoi) was added benzotriazol-1-yloxy-tris(dimethylamino)phosphonium <br><br>
30 hexafluorophosphate (535 mg, 1.21 mmoi) at ambient temperature. The resulting mixture was stirred for 24 hours. The mixture was diluted with ethyl acetate and washed with 1 M aqueous hydrogen chloride, aqueous sodium bicarbonate, and brine. <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -39 <br><br>
WO 98/34918 <br><br>
PCT/EB98/00064 <br><br>
•38* <br><br>
The organic mixture was dried over magnesium sulfate, filtered, and the filtrate was concentrated. The crude residue was purified by silica gel chromatography (elution with 2% methanol in methylene chloride) to provide (2Q,4Q)-4-[2-benzyioxycarbamoyi-1 • (4-methoxy-benzenesulfonyl)-piperidin®-4-carbonyl]-plperazine-1 -carboxyiic acid tert-5 butyl ester as a colorless solid. <br><br>
(i) A mixture of (2B,4R)-4-[2-benzyloxycarbamoyl-1 -(4~methoxy-benzene- sulfonyi)-piperidine-4-carbonyl]-pipefazine-1 -carboxyiic acid tert-butyi ester (500 mg, 0.81 mmoi) and 5% palladium on barium sulfate (250 mg) in 10 mL of methanol was shaken under a 40 psi atmosphere of hydrogen gas for 1.5 hours. Filtration through nylon and 10 concentration of the filtrate provided {2Q,4Q)-4-[2-hydroxycarbamoyM-(4-methoxy-benzenesulfonyl)-piperidine-4-carbonyl]-piperazine-1-carboxylic acid tert-butyi ester as a colorless solid, which was used in the subsequent step without purification. <br><br>
(j) Hydrogen chloride gas was bubbled through a cold (0° C) solution of (2JB.4QH-[2-hydroxycarbamoyM -(4-methoxy-beraenesulfonyl}-piperkfine-4-carbonyi]-piperazine-1 -15 carboxyiic add tert-butyi ester (420 mg, 0.8 mmoi) for 10 minutes. After an additional 20 minutes the mixture was concentrated to provide (2R, 4RJ-1 -(4-methoxy-benzenesulfonyl)-4-(piperazine>1-carbonyl)-piperidine-2-carboxylic add hydroxyamide hydrochloride as a colorless solid: Mass spectrum (atmospheric pressure chemical ionization; basic mode) m& (M+H) 427,366; 'H NMR (dimethyl sulfoxide^, 400 MHz, 20 ppm) 6 10.70 (bd, 1 H, J = 2.7 Hz). 9.06 (bs, 2 H), 8.84 (bs, 1 H), 7.70 (dd, 2 H, J ■ 8.9,2.9 Hz), 7.06 (dd, 2 H, J - 8.9,2.9 Hz), 4.42 (bs, 1 H), 3.80 (s, 3 H), 3.80-3.20 (m, 6 H), 3.04 (m, 4 H), 2.76 (m, 1 H), 1.79 (bd, 1 H, jJ « 13.5 Hz), 1.52 (bd, 1 H, J = 12.6 Hz), 1.32 (m, 1 H) 1.14 (m 1H). <br><br>
Example 2 <br><br>
25 (2B.4R>-1 -f3»f4-FluorophenoxvVpropane-1 -sulfonvH-2-hvdroxvcarbamovl- <br><br>
ptoeridtne-4-carboxvHc acid methvl eater <br><br>
(a) To astirred solution of (2Q,4B)-piparidine-2,4-dicarboxyiic add 2-tert-butvl ester 4-methyl ester (920 mg, 3.78 mmoi) and triethylamine (1.58ml, 11.3 mmoi) in 10 mL of methylene chloride was added a solution of 3-(4-fluorophenoxy)-propane-1-30 sulfonyi chloride (1.05 g, 4.16 mmoi) In 2 mL of methylene chloride under a nitrogen atmosphere. The mixture was stirred for 16 hours at ambient temperature (22 °C), then <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -40- <br><br>
WO 98/34918 <br><br>
PCT/1B98/00064 <br><br>
-39- <br><br>
diluted with 20 mL of 1 N hydrochloric acid and 20 mL of methylene chloride. The organic layer was removed and washed with brine and dried over sodium sulfate. Filtration and concentration of the filtrate gave 2.8 g of a yellow oil, which was purified by flash chromatography (3:2 hexanes/ethyt acetate elution) to give 1.15 g (2FJ,4R)-1 -[3-5 (4-fluoro-phenoxy)-propane-1 -sulfonyl]-piperidine-2,4-dicarboxyiic acid 2-tert-butyl ester 4-methyl ester of as a yellow oil. <br><br>
(b) To a stirred, cold (0 °C) solution of (2B,4g)-1-[3-(4-fluorophenoxy)-propane-1-sulfonyl]-piperidine-2,4-dicarboxylic add 2-tert-butvt ester 4-methyl ester (1.15 g, 2.5 mmoi) in 10 mL of methylene chloride was added 10 mL of trifluroacetic add. The <br><br>
10 mixture was allowed warm to ambient temperature (22 °C) over 16 hours. The mixture was concentrated in vacuo to give 970 mg of crude (2B,4R)-1-[3-(4-fluorophenoxy)-propane-1-sutfonyf]-piperidine-2,4-dicarboxylic acid 4-methyl ester as a orange solid. <br><br>
(c) To a stirred solution of (2fl,4R)-1 -[3-(4-fluorophenoxy)-propane-1 -suffonyl]-piperidine-2,4-dicart>oxytic add 4-methyl ester (970 mg, 2.4 mmoi) in 5 mLof methylene <br><br>
15 chloride was added triethylamine (1.0 ml_ 7.2 mmoi) and Q-benzylhydroxytamine hydrochloride (410 mg, 2.64 mmoi) at ambient temperature (22 °C). To the resulting solution was added benzotriazol-1 -yloxy-tris(dlmethylamino)phosphonium hexaBuorophosphate (1.17 g, 2.64 mmoi) and the mixture was stirred for 16 hours under a nitrogen atmosphere. The mixture was diluted with 25 mL of 1 N hydrochloric 20 add and 25 mL of ethyl acetate. The organic layer was removed and the aqueous layer was extracted with ethyl acetate (2 x). The combined organic layers were washed with saturated aqueous sodium carbonate (1 x) and brine (1 x). The organic layer was dried (sodium sulfate), filtered, and the filtrate was concentrated in vacuo. Purification of the viscous yellow residue by flash chromatography (eiuting with 1:1 ethyl acetate/hexanes) 25 gave 810 mg of (2B,4R)-2-benzyloxycarbamoyl-1 -{3-(4-fluorophenoxy)-propane-1 -sulfonylJ-piperidine-4-carboxylic add methyl ester as a dear oil. <br><br>
(d) A mixture of (2£,4B}-2-benzyloxycart>amoyl-1-[3-(4-fluorophenoxy)-propane-1-sutfonyl]-piperidine-4-carboxylic add methyl ester (800 mg, 1.57 mmoi) and 200 mg of 5% palladium on barium sulfate in 15 mL of methanol was shaken in a Parr apparatus <br><br>
30 under a 40 psi hydrogen gas atmosphere for 2 hours. The catalyst was removed by passage of the mixture through a 0.45 pm nylon filter and the filtrate was concentrated to give 650 mg of (2B,4R)-1-[3-(4-fluorophenoxy)-propane-1-sulfonylJ-2- <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -41- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-40- <br><br>
hydroxycarbamoyl-plperidlne-4-carboxyHc acid methyl ester as a white foam: MS (atmospheric pressure chemical ionization) acidic mode, 417 (M-1); 'H NMR (400 MHz, CDCij) 6 6.94-6.97 (m, 2 fcj), 6.80-6.63 (m, 2 fcj), 4.56 (s, 1 H), 4.03 (t, 2 ft A - 5.3 Hz), 3.83 (d. 1 ft £ - 12.9 Hz), 3.68 (s, 3 KJ), 3.15-3.28 (m, 3 jj), 2.76 (t, 1 ft J » 11.5 Hz), 5 2.54 (d, 1 ft J = 13.5 Hz), 2.26 (d, 2 H. i = 5.9 Hz), 2.02 (m, 1H,J = 13.0 Hz), 1.73-1.78 (m, 1 H), 1.56-1.62 (m, 1 H). <br><br>
ISfflPl* 3 <br><br>
{2R.4RM-r3-/4-FluoroDh«noxvV-orooane-1-aulfonvlT-2-hvdroxvcarbamovl-ptoeridtne-4-carboxvUc acid <br><br>
10 To a stirred, cold (0 °C) solution of (2Q,4R)-1 -[3-(4-fluorophenoxy)-propane-1 - <br><br>
sulfonyl]-2-hydroxycarbnmoyi-piperidin&-4-carboxyiic acid methyl ester (400 mg, 0.96 mmoi) in 5 mL of a methanoi/Water mixture (10:1) was added lithium hydroxide monohydrate (120 mg, 2.88 mmoi). After 3 hours at 0 °C, prerinsed (methanol) Amberlite resin (4.1g) was added. The mixture was filtered and the filtrate was 15 concentrated to give 370 mg of (2B,4Q)-1-[3-(4-fiuorophenoxy)-propane-1-suffonyf]-2-hydroxycarbamoyi-pipeddin»-4-carboxylic acid as a white foam: MS (atmospheric pressure chemical ionization) acidic mode, 403 (M-1). <br><br>
ftqtmpl* 4 <br><br>
(2R.4RWl-r4-f4-Fluorobenzvtoxvl-benzene8ulfonvfl-2-hvdroxvcarbamovl« 20 oloeridlne-4-carboxvllc acid methvl ester <br><br>
4-(4-Fluoro-benzyioxy)-benzen«sutfonyi chloride. MS: 465 (M-1). <br><br>
The titled compound of example 4 was prepared by a method analogous to that described in example 2 using the reagents. <br><br>
Smmplt 5 <br><br>
25 (2R.4RV-1-f4-/4-Fluorobanzyloxv>-benzeneauHonvl'l-2-hvdroxvcarbamovl- <br><br>
p|peridlne-4-carboxvllc acid. MS: 451 (M-1). <br><br>
The titled compound of example 5 was prepared by a method analogous to that described in example 3 starting with 1-[4-(4-Ruoro-benzyloxy)-benzenesuifbnyi]-2-hydroxycarbamoyi-piperidlne-4-carboxyiic acid methyl ester. <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -42- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-41- <br><br>
Exampl* e <br><br>
2R.3S-/1-f4»/4-nuorobenzvloxvy-benzenemjlfonvll-2-hvdroxvcarbamovt-alparidtn-3-wlV-carbamte add laopropvl ester <br><br>
(a) To a stirred, cold (0 °C) solution of the known (Agami, C.; Harnon, L; <br><br>
5 Kadouri-Puchot, C.; Le Guen, V J. Org. Chem. 1996, §1, 5736-5742) [4§-4a,9ar,9aar]-1 -oxo-4-phenyl-octahydro-pyrido[2,1 -£][1,4]oxazin»-9-carboxyllc acid methyl ester (8.2B g, 2.86 mmoi) in 100 mL of tetrahydrofuran was added 2.39 mL of concentrated hydrochloric acid. After 5 minutes the mixture was concentrated to dryness. The resulting solid was suspended in ethyl acetate and the mixture was 10 stirred for an hour. The solids were collected by filtration, rinsed with ethyl acetate, and dried to give 9.04 g of a white solid. <br><br>
Two grams of this solid was dissolved in 26 mL of 6 N hydrochloric acid and heated at reflux for 6 hours. The mixture was cooled to 0 °C and neutralized with 3 N sodium hydroxide and concentrated in vacuo. The resulting solids were 15 suspended in chloroform and passed through a 45 jum nylon filter. The filtrate was concentrated to a yellow oil which was purified by flash chromatography (etuting with 2:1 hexanes/ethyl acetate with 1% acetic acid) to give 802 mg of [4S-4a,9a,9aaf]1-oxo-4-phenyi-octahydro-pyi1do[2,1-s][1,4]oxazine-9-carboxyiic acid as white solid. <br><br>
20 (b) To a stirred solution of [4§-40,9a,9aa]1-oxo-4-phenyi-octahydro- <br><br>
pyrido[2,1-£][1,4]oxazine-9-carboxylic add (568 mg, 2.06 mmoi) in 15 mL of benzene was added triethylamine (0.28 mL, 2.06 mmoi) and diphenyiphosphoryl azide (0.44 mL, 2.06 mmoi) at 22 °C under a nitrogen atmosphere. The mixture was stirred at 22 °C for 45 minutes and at reflux for 50 minutes before 2-propanol (3.2 25 mL, 41.2 mmoi) was added. After an additional 20 hours at reflux the mixture was cooled to 22 °C and concentrated in vacuo. The residue was taken up in ethyl acetate and the resulting solution was washed with 5% citric add, water, saturated aqueous sodium bicarbonate, and brine. The organic layer was dried (sodium sulfate), filtered, and the filtrate was concentrated in vacuo. The yellow residue was 30 purified by flash chromatrography (eluting with 3:1 hexanes/ethyl acetate) to give 402 mg of (4§-4cr,9cr,9aar]{1 -oxo-4-phenyt-octahydro-pyrido[2,1 -£] [1,4]oxazin-9-yl)-carbamic add isopropy) ester as white solid. <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -43- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-42- <br><br>
(c) A mixture of [4§-4o,9o,9ao](1 -oxo-4-phenyl-octahydro-pyrido[2,1 -c][1,4]oxazin-9-yl)-carbamic acid isopropyl ester (900 mg , 2.71 mmoi) and 20% palladium hydroxide on carbon (920 mg) in 77 mL of ethanol/water (10:1) was shaken in a Parr apparatus under a 45 psi hydrogen gas atmosphere for 72 hours. <br><br>
5 The catalyst was removed by passage of the mixture through a 0.45 /jm nylon filter and the filtrate was concentrated to give 610 mg of 2B.3S-3-isopropoxycart>onyJamino-piperidine-2-carboxylic acid as white solid. MS: 229 (M-1). <br><br>
(d) To a stirred solution of 2B,3§-3-Jsopropoxycarbonylamino-piperidine-2-carboxylic acid (320 mg, 1.39 mmoi) in 5 mL of methylene chloride was added <br><br>
10 triethylamine (0.58 ml_ 4.17 mmoi) followed by 4-(4-fluorobenzyloxy)- <br><br>
benzenesulfonyl chloride (460 mg, 1.53 mmoi). After 16 hours at 22 °C the mixture was portioned between 1 N hydrochloric acid and ethyl acetate. The organic layer was removed and washed with brine and dried over sodium sulfate. Filtration and concentration of the filtrate gave 480 mg of crude 2B.3S-1 -[4-(4-fluorobenzyloxy)-15 benzenesuifonyl]-3-<sopropoxycarbonyiamino-piperfdine-2-carboxytic add as a light yellow solid. <br><br>
(e) To a stirred, cold (0 °C) solution of crude 2B,3§-1-[4-(4-ftuorobenzyloxy)-benzenesulfonyl]-3-i*opropoxycarbonyl amino-piperidine-2-carboxylic acid (380 mg, 0.77 mmoi) in 5 mL of methylene chloride was added <br><br>
20 triethylamine (0.32 mL, 2.31 mmoi) followed by benzotriazol-1 -yioxy- <br><br>
tris(dimethyiamino)phosphonium hexafluorophosphate (510 mg, 1.15 mmoi). The resulting solution was stirred for 2 minutes at 0 °C under a nitrogen atmosphere before 0-(trimethy)sitylethyi)hydroxylamine hydrochloride (195 mg, 1.15 mmoi) was added. The mixture was allowed to warm slowly to 22 °C over 14 hours. The 25 mixture was concentrated in vacuo and the residue was diluted with water and extracted with ethyl acetate/diethyl ether (1:1; 3 x). The combined organic extracts were washed with saturated aqueous carbonate (2 x), water (2 x), and brine (1 x). The organic layer was dried (magnesium sulfate), filtered, and the filtrate was concentrated in vacuo. The yellow residue was purified by flash chromatography 30 (eluting with 65:35 hexanes/ethyl acetate) to give 300 mg of 2R,3S-[1-[4-(4- <br><br>
fluorobenzyfoxy)-benzenesulfonyl]-2-(2-trimethyl8ilanyl-ethoxycarbamoyl)-piperidin-3-yf]-carbamic acid isopropyl ester as a white foam. MS: 610 (M+1). <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -44- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-43- <br><br>
(f) To a stirred, cold (0 °C) solution of 2S,3S-[1 -(4-(4-fIuorobenzyfoxy)-benzenesulfonyl]-2-{2-trimethytsilanyi-«thoxycart3anioyl)-piperidin-3-yl]-cart>amic acid isopropyl ester (265 mg, 0.44 mmoi) in 4 mL of methylene chloride was added 3 mL of trifluoroacetic acid. The resulting colorless solution was allowed to warm to 23 °C 5 over 2 hours and was stirred for an additional 28 hours. The mixture was concentrated in vacuo to a solid/foam, which was suspended in ethyl acetate hexanes (1:6) and stirred for 10 hours. The white solids were collected by filtration, rinsed with hexanes, and purified further by flash chromatography (eluting with 7:3 ethyl acetate/hexanes with 1% acetic acid) to give 130 mg of 2f3,3S-1-{4-(4-10 fluorobenzyloxy)benzenesulfony1]-2-hydroxycart>amoyi-plperidin-3-yl}-carbainic add isopropyl ester as a white solid/foam. MS: 510 (M+1). <br><br>
Example 7 <br><br>
3-($)-4-(4'-F1uofoblphenYl-4^ulfonYl)-2,2-dimethYi-thioniorphp|lne-3-c?rbpxyllc acid frYdroyyqmltfr <br><br>
15 (a) To a stirred solution of the known (PCT Publication WO 97/20824) 3- <br><br>
(S)-dimethytthexytsilyl-2,2-d4methyl-tetrahydro-2tl-1,4-thiazine-3-carboxyiate (1.17 g, 3.70 mmoi) in 6 mL of methylene chloride was added triethylamine (1.02 mL, 7.40 mmoi) followed by 4-fluorobiphenyisulfonyl chloride (1.0 g, 3.70 mmoi). The resulting solution was stirred for 56 hours at 23 °C. The reaction mixture was diluted 20 with methylene chloride and washed with water. The organic layer was concentrated in vacuo; the residue was dissolved in methanol, and the mixture was heated at reflux for 6 hours. The mixture was cooled to 23 °C and concentrated in vacuo. The residue was purified by flash chromatography (eluting with 3:7 ethyl acetate/hexanes with 0.1% acetic acid) to give 670 mg of 3-(§)-4-(4'-fluorobiphenyl-4-sulfonyl)-2^2-25 dimethyMhiomorpholine-3-carboxylic acid as a white foam/solid. MS: 427 (M+NH4). <br><br>
(b) To a stirred, cold (0 °C) solution of 3-(S)-4-(4'-fluorobiphenyl-4-suifonyl)-2,2-dimethyWhiomorpholine-3-carboxylic acid (605 mg, 1.48 mmoi) in 5 mL of methylene chloride was added triethylamine (0.62 mL, 4.43 mmoi) under a nitrogen atmosphere. Benzotriazol-1 •y(oxy-tris(dimethytamino)phosphonium 30 hexafluorophosphate (980 mg, 2.22 mmoi) was added and the resulting solution was stirred for 5 minutes before 2-(trimethyisilyiethyi)hydroxylamine hydrochloride (376 mg, 2.22 mmoi) was added. The Ice bath was removed and the mixture was <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -45 <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-44- <br><br>
stirred for 20 hours at 23 °C. The mixture was diluted with aqueous ammonium chloride and extracted with 1:1 ethyl acetate/dlethyi ether (3 x). The combined organic extracts were washed with saturated aqueous sodium carbonate (2 x), water (1 x), and brine (1 x). The organic layer was dried (magnesium sulfate), filtered, and 5 the filtrate was concentrated in vacuo. The residual yellow oil was purified by Hash chromatography (eluting with 3:7 ethyl acetate/hexanes) to give 660 mg of 3-{S)-4-(4'-fluorobiphenyl-4-sulfonyl}-2,2-dimethyMhiomorphollne-3-carboxyiic acid (2-trimethylsiianyi-ethoxy)-amide as a white foam. MS: 523 (M-1). <br><br>
(c) A solution of 3-(§)-4-(4'-fiuorobiphenyi-4-sulfonyl)-2,2-dimethyl-10 thiomorpholine-3-carboxyiic add (2-trimethylsilanyt-ethoxy)-amide (650 mg, 1.24 mmoi) in 8 mL of trifluoroacetic add was stirred for at 22 °C for 16 hours. The mixture was concentrated in vacuo and the residue was triturated with methylene chloride and diethyl ether. The solvent was removed to give 550 mg of a tan solid. The solid was suspended in 1:1 diethyl ether/hexanes and stirred gently for 20 15 hours. The solids were collected by filtration (1:1 diethyl ether/hexanes rinsing) and dried to give 470 mg of 3-(§)-4-(4'-fluorobiphenyl-4-eulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide as white solid. MS: 423 (M-1). <br><br>
ftmrrnh f <br><br>
3-(S)-4-r4-/4-Fiuorobenrvloxv)bsnzene»ulfonvn-2.2-dlmethvl-20 thiomomhoHne-3 -carboxvllc acid hvdroxvamlde <br><br>
(a) To a stirred, cold (0 °C) solution of the known (Belgian Patent Publication BE 893025) 2,2-dimethyt-thiomorphoiine*3-carboxylic acid (600 mg, 3.42 mmoi) in 10 mL of 1:1 water/dioxane was added 6 N sodium hydroxide (1.2 mL, 7.1 mmoi). To the resulting solution 4-(4-fluorobenzyioxy)benzenesulfonyi chloride (1.08 25 g, 3.77 mmoi) was added. After 30 and 60 minutes an additional 1 gram of 4-(4-fluorobenzyioxy)benzeneeuifonyt chloride and 1.2 mL of 6 N sodium hydroxide was added. The mixture (pH ca. 12) was diluted with water and extracted with diethyl ether (1 x). The ethereal layer was washed with 1 N sodium hydroxide; the combined basic aqueous layers were acidified to pH 3 using concentrated 30 hydrochloric add, and the addic mixture was extracted with ethyl acetate (3 x). The combined organic extracts were dried (sodium sulfate), filtered, and the filtrate was concentrated in vacuo to give 820 mg of 3-(§)-4-[4-(4- <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -46- <br><br>
V <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
-46- <br><br>
fluorobenzyloxy)benzenesuHonyl]-2,2-dimethyi-thiomorpholine-3-carboxylic acid as a white solid. MS: 438 (M-1). <br><br>
(b) To a stirred, odd (0 °C) solution of 3-(§)-4-[4-(4-fluorobenzytoxy)-benzenesuHonyi]-2,2-dimethyi-thiomorpholine-3-carboxylie add (820 mg, 1.87 mmoi) <br><br>
5 in 5 mL of methylene chloride was added triethylamine (0.52 mL, 3.74 mmoi) under a nitrogen atmosphere. Benzotriazol-1 -ytoxy-tHs(dim«thytamino)phosphonium hexafiuorophosphate (1.24 g, 2.81 mmoi) was added and the resulting solution was stirred for 5 minutes before O-rtert-butvidimethvtsilvilhvdroxvlamine (550 mg, 3.74 mmoi) was added .The ice bath was removed and the mixture was stirred for 16 10 hours at 23 °C. Hie mixture was diluted with aqueous ammonium chloride and extracted with ethyl acetate (3 x). The combined organic extracts were washed with water, brine, and dried over sodium sulfate. Filtration and concentration of the filtrate gave a viscous yellow oil, which was purified by flash chromatography (eluting with 1:3 ethyl acetate/hexanes) to give 270 mg of 3-(S)-4-{4-{4-15 fluorobenzyioxy)benzenesuffonyl]-2,2-dlmethyl-thlomorphollne-3-cart}oxylic acid ftert-butyidimethylsiloxy)-amide as a white foam. MS: 569 (M+1). <br><br>
(c) To a stirred, cold (0 °C) solution of 3-(§)-4-[4-(4-fluorobenzyloxy)-benzenesulfonyl] -2,2-dimethyf-thiomorphoiine-3-carboxyiic acid ftert-butyidimethyisiioxy)-amide (270 mg, 0.47 mmoQ in 10 mL of tetrahydrofuran was <br><br>
20 added two drops of concentrated hydrochloric acid. After 30 minutes the mixture was diluted with 15 mL of tetrahydrofuran and the mixture was concentrated in vacuo to a volume of ca. 5 mL The volume was adjusted to ca. 25 mL with tetrahyrofuran and the mixture was concentrated again to ca. 5 mL This process was repeated twice more before the mixture was finally concentrated to dryness. 25 The resulting solids were suspended in a mixture of hexanes and diethyl ether and the mixture was stirred for 16 hours. The solid were collected by filtration, rinsed with diethyl ether,and dried to give 180 mg of 3-(§)-4-[4-{4- <br><br>
fluorobenzytoxy)benzenesutfonyi]-2,2-dimethyMhiomorpholine-3 -carboxyiic add hydroxyamide as a white solid. MS: 453 (M-1). 'H NMR (400 MHz, dmso-d^ 6 10.63 30 (s, 1 tfl, 8.80 (bs, 1 fcD 7.59-7.61 (m, 2 jj), 7.46-7.50 (m, 2 fci), 7.17-7.21 (m, 2 H). 7.09-7.12 (m, 2 fcD, 5.12 (s, 2 fcD, 3.99 (s, 1 fcD, 3.87-3.93 (m, 1 fcD. 3.69 (d, 1 H. J = 12.7 Hz). 2.78-2.86 (m, 1 fci), 2.44-2.50 (m, 1 H), 1.35 (s, 3 JH), 1.12 (s, 3fcfi. <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -47- <br><br>
WO 98/34918 <br><br>
PCT/IB98/00064 <br><br>
•46- <br><br>
Praparatlon 1 4-f4»FluorobenzvtoxvM>enzeneauHonvi chloride <br><br>
To a stirred solution of 4-hydroxybenzenesuifonic add sodium salt dihydrate (5.13 g, 22.1 mmoi) in 23 mL of 1 N sodium hydroxide was addad a solution of 4-5 fluorobenzyt bromide (3.3 mL, 26.5 mmoi) in 20 mL of ethanol. The mixture was heated at reflux for two days, then cooled to ambient temperature (22 °C), whereupon a white precipitate formed. The flaky white solids were collected by filtration, rinsed with ethyt acetate and diethyl ether, and dried to give 4. 95 g of 4-(4-fluoro-benzyioxy)-benzenesuifonic add sodium salt. A stirred solution of 4-{4-fluoro-10 benzyioxy)-benzenesulfonic add sodium salt (13.0 g, 42.7 mmoi) in 50 mL of thionyi chloride and two drops of dimethyiformamide was heated at a gentle reflux for 8 hours. The mixture was concentrated to a yellow solid which was suspended in ethyl acetate and filtered. The filtrate was concentrated to 11.2 g of 4-(4-fluorobenzyioxy)benzenesutfonyi chloride as a light yellow solid: 'H NMR (400 MHz, 15 CDCIj) 5 7.95-7.98 (m, 2 H), 7.38-7.41 (m, 2 fcD, 7.08-7.12 (m, 4 H), 5.12 (s, 2 fcj). <br><br>
Prwwnttan Z <br><br>
3-(4-FiuorophenoxvV-oropane-1 -sulfonvi chloride <br><br>
To a stirred solution of 4-fluorophenol (5.0 g, 44.6 mmoi) in 50 mL of toluene was added sodium hydride (60% dispersion in mineral oil, 1.78 g, 44.6 mmoi) at 20 ambient temperature (22 °C). After 20 minutes, a solution of 1,3-propane sutfone (3.9 mL, 44.6 mmoi) in toluene was added slowly and the mixture was stirred for 16 hours. The reartion was quenched by the addition of methanol and the mixture was concentrated in vacuo to an off-white solid. This solid was suspended in ethyl acetate, filtered, and the solids were collected and dried to give 10.9 g of 3-{4-25 fiuorophenoxy)-propane-1 -sulfonic acid sodium salt as an off-white powder. A stirred solution of 3-{4-fluorophenoxy)-propane-1 -sulfonic add sodium salt (2.0 g, 7.8 mmoi) in 10 mL of thionyi chloride and one drops of dimethyiformamide was heated at reflux for 16 hours. The mixture was then cooled to 0 °C, diluted with 25 mL of diethyl ether, and Vie reaction was quenched by the slow addition of water. The 30 organic layer was removed and the aqueous layer was extracted with 25 mL of diethyl ether. The combined organic layers were washed with brine and dried over <br><br>
Printed from Mimosa 07/26/1999 10:15:38 page -48- <br><br>
WO 98/34918 <br><br>
PCT/IJJ98/00064 <br><br>
-47- <br><br>
sodium sulfate. Filtration and concentration gave 1.75 g of 3-(4-fluoro-phenoxy)-propane-1-suifonyl chloride as a yellow oil: 1H NMR (400 MHz, CDCI,) 6 6.96-7.00 (m, 2 H), 6.80-6.84 (m, 2 H), 4.10 (t, 2 H, J = 5.5 Hz), 3.91 (t, 2 M, J - 7.5 Hz) 2.47-2.54 (m, 2 tD- <br><br>
5 Preparation 3 <br><br>
4'-Fluorobluhenvlsulfonvt chloride <br><br>
Chlorosulfonic acid (8.7 mL, 0.13 mole) was added dropwise to stirred cold (0 °C) 4-fluoroblphenyl (10.2 g, 59 mmoi). After 30 minutes at 0 °C the reaction mixture was poured onto ice. The resulting white precipitate was collected by 10 filtration and dissolved in chloroform. The chloroform solution was washed with water, brine, dried over magnesium sulfate, and concentrated to afford a white solid. The desired 4Mluorobiphenyisuifonyl chloride (4.3 g), was separated from 4'* fluorobiphenylsutfonic acid by crystallization of the latter from ethyl acetate and crystallization of the remaining material from hexanes. <br><br>
Printed from Mimosa 07/26/1999 <br><br>
10:15:38 page -49- <br><br></p>
</div>
Claims (4)
1 * jul 2000<br><br> RECEIVED<br><br> -57-<br><br> <«>„ 11<br><br> <ch2)n wherein n is 0 to 6;<br><br> yisOorl;<br><br> W is oxygen or >NR*4;<br><br> Z is -OR11, -NR24R11, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl or a bridged diazabicycloalkyl ring selected from the group consisting of<br><br> <ch2)m<br><br> <CHE>m<br><br> V<br><br> cch2>r y<br><br> N<br><br> <CH<br><br>
2>r<br><br> <ch2)p wherein r is 1,2 or 3; m is 1 or 2; pis0or1;and<br><br> INTELLECTUAL PROPERTY OFFICE OF N.Z.<br><br> 1 * jul 2000<br><br> RECEIVED<br><br> ""T~? c-j<br><br> ■\ £ O<br><br> - 58 - vy ^ W [T<br><br> V is hydrogen, (Ct^alkyl, (C1-C6)alkyl(C=0)-, (Q-Cg) alkoxy(C=0)-, (Cg-Cio)aryl(C=0)-, (Cg-Cio)aryloxy(C=0)-, (Cg-Cio)aryl(Ci-Cg)alkyl(C=0)-, (Ce-Cio)aryl-(Ci-C6)alkoxy(C=0)-, or (C,-C6)alkoxy(C=0)-0-;<br><br> wherein each heterocyclic group may optionally be independently substituted by one or two groups selected from hydroxy, (Q-Cgjalkyl, (CVQOalkoxy, (CrCmJacyl, (C^C^Jacyloxy, (Cg-C10)aryl, (C2-C9)heteroaryl, (Cg-C^aryKCVC^alkyl, (Cz-C^heteroaryKCrCgJalkyl, hydroxyCCrCgJalkyl, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)acyloxy(C1-C6)alkyl, (C^CgJalkylthio, (Cr C6)alkylthio(CrC6)alkyl, (Cg-C10)arylthio, (C6-C10)arylthio(C1-C6)alkyl, R12R13N-, R12R13NS02-, R12R13N(C=0)-, R12R13N(C=OHC1-Cg)alkyl, R14SOr, R14S02NH-, R15(C=0)-[N(R12)]-, R160(C=0)-, or R180(C=0)-(C1-C6)alkyl;<br><br> wherein R10 is (CrC6)acylpiperazinyl, (C8-C10)arylpiperazinyl, (C2-C9)heteroarylpiperazinyl, (CrCg)alkylpiperazinyl, (C6-C10)aryl(C1-C6)alkylpiperazinyl, (Q,-C9)heteroaryl(C1-C6)alkylpiperazinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidyl, (Q-Ce)alkylpiperidyl, (C6-C10)arylpiperidyl, (C2-C9)heteroarylpiperidyl, (Q-CgJalkylpiperidyKC,-C8)alkyl, (Cg-C10)arylpiperidyl(C1-C6)alkyl, (Qz-CJheteroaryl-piperidyKCrCg^lkyl or (Cr C6)acylpiperidyl;<br><br> R11 is hydrogen, (CB-C10)aryl, (Ca-Cgjheteroaryl, (Cg-Cio)aryl(CrC6)alkyl, (Cr CaJheteroaryKCi-CgJalkyl, (C1-C6)alkyl(C6-C10)aryl(C1-Ce)alkyl, (C1-C6)alkyl(C2-C9)heteroaryl(C1-C6)alkyl, 5-indanyl, -CHR170-(C=0)-R18 or -CH2(C=0)-NR19R20;<br><br> R12 and R13 are each independently hydrogen, (C,-C6)alkyl, (Ce-C10)aryl, (Q>-Cg)heteroaryl, (Cg-C1o)aryl(C1-Cg)alkyl or (C^-C^heteroaryKCrCeJalkyl or R12 and R13 may be taken together with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or thiomorpholinyl ring;<br><br> R14 is trifluoromethyl, (C,-C6)alkyl, (C6-C10)aryl, (C2-C9)heteroaryl, (Cg-C^aryKCr C6)alkyl or (C2-G9)heteroaryl(C1-C6)alkyl;<br><br> R15 is hydrogen, (CrCg)alkyl, (C^CgJalkoxy, (Ce-C10)aryl, (C2-C9)heteroaryl, (Cr Cg)aryl(C1-C6)alkyl(Cg-C10)aryl(C1-C6)alkoxy or (Cg-CgJheteroaryKCrCoJalkyl;<br><br> R16 is (CrCgJalkyl, (Ce-C10)aryl, (C2-C9)heteroaryl, (Cg-C^JaryKC^gJalkyl, 5-indanyl, -[CH(R17)]0-(C=0)-R18, -CH2(C=O)-NR19R20i or R210(CrC8)alkyl;<br><br> R17 is hydrogen or (C^CgJalkyl;<br><br> R18 is (Q-CeJalkyl, (C^CgJalkoxy or (C8-C10)aryl;<br><br> R19 and R20 are each independently hydrogen or (C,-C6)alkyl or may be taken together with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or thiomopholinyl ring;<br><br> INTELLECTUAL PROPERTY OFFICE OF N.Z.<br><br> m jul 2000<br><br> RECEIVED<br><br> -59-<br><br> ^36836<br><br> R21 is H2N(CHR22)(C=0)-;<br><br> R22 is the side chain of a natural D- or L-amino acid;<br><br> R23 is hydrogen, (C1-C6)acyl, (C1-C6)alkyl, (Cg-C^JaryKCrC^alkyl, (CVC^heteroaryKCr CB)alkyl or (C^-CsJalkylsulfonyl;<br><br> R24 wherever it occurs is independently hydrogen or (C,-C6)alkyl;<br><br> or R1 and R2, or R3 and R4, or R5 and R6 may be taken together to form a carbonyl; or R1 and R2, or R3 and R4, or R5 and R6, or R7 and R8 may be taken together to form a (C3-C6)cycloalkyl, oxacyclohexyl, thiocyclohexyl, indanyl or tetralinyl ring or a group of the<br><br> Q is (Cs-C10)aryi(C1-C8)alkoxy(C6-C10)aryl optionally substituted by fluoro, chloro, (Cn-C^aikyl, (C1-C,)alkoxy or perfluoro(C1-C3)alkyl;<br><br> with the proviso that when R1, R2, R3, R4, R5, R6, R7, R*, and R9 are all defined by hydrogen or (C1-Cs)alkyl, the broken line represents a double bond;<br><br> with the proviso that when R1, R2 and R9 are a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 2- or 6- positions of the ring;<br><br> with the proviso that when y is 1 and W is NF?4 or oxygen, Z cannot be hydroxy;<br><br> with the proviso that when the broken line represents a double bond, R4 and R6 are not present;<br><br> with the proviso that when R3 and R5 are independently a substituent comprising a heteroatom when the broken line represents a double bond, the heteroatom cannot be directly bonded to positions X and Y.<br><br> 4. A compound according to claim 1, wherein R2, R3, R6, R7 and R9 are hydrogen.<br><br> 5. A compound according to claim 1, wherein at least one of R7-R9 is other than hydrogen.<br><br> formula<br><br> R23<br><br> 6.<br><br> R7-R9 is (CrC^alkyl.<br><br> A compound according to claim 1, wherein at least one of intellectual property office of N.Z.<br><br> - 5 DEC 2000<br><br> RECEIVED<br><br> j36836<br><br> -60-<br><br> 7. A compound according to claim 1, wherein in at least one of R7-R9 is methyl.<br><br> 8. A compound according to claim 1, wherein R7 and R8 are taken together to form a carbonyl and R9 is ((VCelalkyl.<br><br> 9. A compound according to claim 1, wherein R7 and R8 are each methyl.<br><br> 10. A compound according to claim 1, wherein R7 arid R8 are taken together to form a (C3-C6)cycloalkyl group.<br><br> 11. A corripound according to claim 1, wherein R1-R9 are hydrogen, hydroxy or (C,-C6)-alkyl and Q is benzyloxyphenyl.<br><br> 12. A compound according to claim 1, wherein said compound is selected from the group consisting of:<br><br> # (2f?,4f?)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidine-4-<br><br> carboxyiic acid;<br><br> (2R,4R)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyi]-2-hydroxycarbamoyl-piperidine-4-carboxyiic acid methyl ester;<br><br> (2R,4f?)-1-[3-(4-Fluorophenoxy)-propane-1-sulfonyQ-2-hydroxycarbamoyl-piperidine-4-carboxyiic add;<br><br> (2R,4/?)-1-[3-(4-Fluorophenoxy)-propane-1-sulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxyiic acid methyl ester;<br><br> (2ft,3SHH4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidin-3-yl}-carbamic acid isopropyl ester;<br><br>
3-(S)-
4-{4'-Fluorobiphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide;<br><br> ^ 3-{S)-4-[4-{4-Fluorobenzyloxy)benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3 -<br><br> carboxyiic acid hydroxyamide;<br><br> (2R,4S)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-4-hydroxy-piperidine-2-carboxylic acid hydroxyamide; and<br><br> (2R,4R)-1-(4-Methoxybenzenesulfonyl)-4-(piperazine-1-carbonyl)-piperidine-2-carboxylic acid hydroxyamide hydrochloride.<br><br> 13. A pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis,<br><br> and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (iTNO or (b) tho inhi intellectual prope<br><br> -inhibitio n of property office OF n.z.<br><br> - 5 DEC 2000<br><br> RECEIVED<br><br> 336836<br><br> matrix metalloproteinases or the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising an amount of a compound of claim 1 effective in such treatment and a pharmaceuticaily acceptable carrier.<br><br> 14. A pharmaceutical composition as claimed in claim 13, wherein said composition further comprises a standard NSAID, analgesic or cytotoxic anticancer agent.<br><br> 15. The use of an effective amount of a compound of claim 1 in the manufacture of a medicament for the inhibition of (a) matrix metalloproteinases or (b) the production of tumor necrosis factor (TNF) in a mammal, including a human.<br><br> 16. The use of an effective amount of a compound of claim 1, in the manufacture of a medicament for treating a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) in a mammal, including a human.<br><br> 17. Use as claimed in claim 16, wherein the medicament further comprises a standard NSAID, analgesic or cytotoxic anticancer agent.<br><br> 18. Use as claimed in claim 17, wherein said medicament is formulated for simultaneous or sequential administration of the NSAID, analgesic or cytotoxic anticancer agent.<br><br> 19. A compound of formula (I) as claimed in claim 1 substantially as herein described or exemplified.<br><br> 20. A pharmaceutical composition as claimed in claim 13 substantially as herein described or exemplified.<br><br> 21. A use as claimed in claim 15 or 16 substantially as herein described or exemplified.<br><br> intellectual property office of n.z.<br><br> 2 1 dec 2000 received<br><br> END<br><br> </p> </div>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3760097P | 1997-02-11 | 1997-02-11 | |
PCT/IB1998/000064 WO1998034918A1 (en) | 1997-02-11 | 1998-01-16 | Arylsulfonyl hydroxamic acid derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ336836A true NZ336836A (en) | 2001-02-23 |
Family
ID=21895216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ336836A NZ336836A (en) | 1997-02-11 | 1998-01-16 | Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments |
Country Status (37)
Country | Link |
---|---|
US (1) | US6599890B1 (en) |
EP (1) | EP0960098A1 (en) |
JP (1) | JP3710489B2 (en) |
KR (1) | KR20000070923A (en) |
CN (1) | CN1247531A (en) |
AP (1) | AP958A (en) |
AR (1) | AR011123A1 (en) |
AU (1) | AU722784B2 (en) |
BG (1) | BG63430B1 (en) |
BR (1) | BR9807678A (en) |
CA (1) | CA2280151C (en) |
CO (1) | CO4950619A1 (en) |
DZ (1) | DZ2416A1 (en) |
EA (1) | EA002546B1 (en) |
GT (1) | GT199800026A (en) |
HN (1) | HN1998000020A (en) |
HR (1) | HRP980070B1 (en) |
HU (1) | HUP0000657A3 (en) |
ID (1) | ID22809A (en) |
IL (1) | IL131123A0 (en) |
IS (1) | IS5130A (en) |
MA (1) | MA24469A1 (en) |
NO (1) | NO993836L (en) |
NZ (1) | NZ336836A (en) |
OA (1) | OA11142A (en) |
PA (1) | PA8446101A1 (en) |
PE (1) | PE58699A1 (en) |
PL (1) | PL334997A1 (en) |
SA (1) | SA98180856A (en) |
SK (1) | SK101399A3 (en) |
TN (1) | TNSN98025A1 (en) |
TR (1) | TR199901926T2 (en) |
TW (1) | TW502020B (en) |
UY (1) | UY24880A1 (en) |
WO (1) | WO1998034918A1 (en) |
YU (1) | YU37499A (en) |
ZA (1) | ZA981061B (en) |
Families Citing this family (278)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA002546B1 (en) * | 1997-02-11 | 2002-06-27 | Пфайзер Инк. | Arylsulfonyl hydroxamic acid derivatives |
AU3982599A (en) | 1998-05-14 | 1999-11-29 | Du Pont Pharmaceuticals Company | Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors |
UA59453C2 (en) * | 1998-08-12 | 2003-09-15 | Пфайзер Продактс Інк. | HYDROXYPIPECOLATE HYDROXAMIC ACID DERIVATIVES AS matrix metalloproteinase inhibitors |
ES2242402T3 (en) * | 1998-08-12 | 2005-11-01 | Pfizer Products Inc. | TACE INHIBITORS. |
AU6228499A (en) * | 1998-10-22 | 2000-05-08 | Akzo Nobel N.V. | Tetrahydropyridopyridine derivatives and intermediates for producing the same |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
CN1178915C (en) | 1999-01-27 | 2004-12-08 | 惠氏控股有限公司 | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (MMP) inhibitors/TNF-alpha converting enzyme (TACE) inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
EP1081137A1 (en) | 1999-08-12 | 2001-03-07 | Pfizer Products Inc. | Selective inhibitors of aggrecanase in osteoarthritis treatment |
UA74803C2 (en) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use |
US6462063B1 (en) | 2000-02-04 | 2002-10-08 | Fibrogen, Inc. | C-proteinase inhibitors |
US6458822B2 (en) | 2000-03-13 | 2002-10-01 | Pfizer Inc. | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases |
EP1138680A1 (en) * | 2000-03-29 | 2001-10-04 | Pfizer Products Inc. | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors |
GB0011409D0 (en) * | 2000-05-11 | 2000-06-28 | Smithkline Beecham Plc | Novel compounds |
JP2001322977A (en) * | 2000-05-12 | 2001-11-20 | Kotobuki Seiyaku Kk | Pipecolic acid derivative and method for producing the same and pharmaceutical composition containing the same |
NZ569856A (en) | 2001-01-05 | 2010-03-26 | Pfizer | Antibodies to insulin-like growth factor 1 receptor |
MXPA01013326A (en) * | 2001-02-14 | 2002-08-26 | Warner Lambert Co | Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors. |
MXPA01013171A (en) | 2001-02-14 | 2004-05-21 | Warner Lambert Co | Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors. |
MXPA01013172A (en) * | 2001-02-14 | 2002-08-21 | Warner Lambert Co | Sulfonamide matrix metalloproteinase inhibitors. |
AU2002345792A1 (en) | 2001-06-21 | 2003-01-08 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
AUPR726201A0 (en) * | 2001-08-24 | 2001-09-20 | Fujisawa Pharmaceutical Co., Ltd. | New use of a cyclic compound |
BR0213736A (en) | 2001-11-01 | 2004-10-19 | Wyeth Corp | allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
AR039067A1 (en) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
WO2003074529A2 (en) | 2002-03-01 | 2003-09-12 | Pfizer Inc. | iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS |
DK3000810T3 (en) | 2002-03-13 | 2017-10-16 | Array Biopharma Inc | N3-ALKYLED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR |
ES2425013T3 (en) | 2002-06-12 | 2013-10-10 | Symphony Evolution, Inc. | Human ADAM-10 inhibitors |
UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
EP1585743B1 (en) | 2002-12-19 | 2007-05-23 | Pfizer Inc. | 2-(1h-indazol-6-ylamino)- benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases |
AU2003304456A1 (en) | 2002-12-23 | 2005-03-16 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
WO2004076412A2 (en) | 2003-02-26 | 2004-09-10 | Sugen, Inc. | Aminoheteroaryl compounds as protein kinase inhibitors |
ATE412655T1 (en) | 2003-08-29 | 2008-11-15 | Pfizer | THIENOPYRIDINPHENYLACETAMIDE AND DERIVATIVES THEREOF SUITABLE AS NEW ANTIANGIOGENIC AGENTS |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
AR045563A1 (en) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | ANTIBODIES DIRECTED TO M-CSF |
CN1905873A (en) | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Bicyclic inhibitors of MEK and methods of use thereof |
GT200500139A (en) * | 2004-06-08 | 2005-07-25 | METHOD FOR THE PREPARATION OF HYDROXAMIC ACIDS | |
EA013678B1 (en) | 2004-08-26 | 2010-06-30 | Пфайзер Инк. | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
CA2608201C (en) | 2005-05-18 | 2013-12-31 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
ES2374450T3 (en) | 2005-09-20 | 2012-02-16 | OSI Pharmaceuticals, LLC | ANTI-BANGEOUS RESPONSE BIOLOGICAL MARKERS FOR KINNER INHIBITORS OF THE GROWTH FACTOR RECEIVER 1 SIMILAR TO INSULIN. |
TWI405756B (en) | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | Novel hydrogen sulfate salt |
US7842836B2 (en) | 2006-04-11 | 2010-11-30 | Ardea Biosciences | N-aryl-N'alkyl sulfamides as MEK inhibitors |
CN101454004B (en) | 2006-04-18 | 2013-12-04 | 阿迪亚生命科学公司 | Pyridone sulfonamides and pyridone sulfamides as mek inhibitors |
US20100029615A1 (en) | 2006-12-15 | 2010-02-04 | Michael John Munchhof | Benzimidazole derivatives |
EA200900959A1 (en) | 2007-01-19 | 2010-02-26 | Арди Байосайенсиз, Инк. | MEK INHIBITORS |
CA2684447C (en) | 2007-04-18 | 2012-01-24 | Pfizer Products Inc. | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
US8530463B2 (en) | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
CA2924418A1 (en) | 2007-07-30 | 2009-02-05 | Jean-Michel Vernier | Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same |
MX2010006800A (en) | 2007-12-19 | 2010-10-05 | Genentech Inc | 5-anilinoimidazopyridines and methods of use. |
KR101660050B1 (en) | 2008-01-04 | 2016-09-26 | 인텔리카인, 엘엘씨 | Certain chemical entities, compositions and methods |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
EP2252293B1 (en) | 2008-03-14 | 2018-06-27 | Intellikine, LLC | Kinase inhibitors and methods of use |
ES2586032T3 (en) | 2008-03-28 | 2016-10-11 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
NZ590258A (en) | 2008-07-08 | 2013-10-25 | Intellikine Llc | Kinase inhibitors and methods of use |
US8476410B2 (en) | 2008-10-16 | 2013-07-02 | University of Pittsburgh—of the Commonwealth System of Higher Education | Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
NZ594177A (en) | 2009-02-05 | 2014-02-28 | Immunogen Inc | Novel benzodiazepine derivatives |
WO2010090764A1 (en) | 2009-02-09 | 2010-08-12 | Supergen, Inc. | Pyrrolopyrimidinyl axl kinase inhibitors |
WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
WO2010099137A2 (en) | 2009-02-26 | 2010-09-02 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the emt status of tumor cells in vivo |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
JP2012519282A (en) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | Methods for identifying mesenchymal tumor cells or agents that inhibit their production |
WO2010098866A1 (en) | 2009-02-27 | 2010-09-02 | Supergen, Inc. | Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors |
JP2012519281A (en) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | Methods for identifying mesenchymal tumor cells or agents that inhibit their production |
US8673919B2 (en) | 2009-03-27 | 2014-03-18 | Ardea Biosciences, Inc. | Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors |
WO2010129816A2 (en) | 2009-05-07 | 2010-11-11 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
JP2013500991A (en) | 2009-07-31 | 2013-01-10 | オーエスアイ・ファーマシューティカルズ,エルエルシー | mTOR inhibitor and angiogenesis inhibitor combination therapy |
IN2012DN01961A (en) | 2009-08-17 | 2015-08-21 | Intellikine Llc | |
CA2772194A1 (en) | 2009-09-01 | 2011-03-10 | Pfizer Inc. | Benzimidazole derivatives |
AU2010306830C1 (en) | 2009-10-13 | 2015-05-28 | Allomek Therapeutics Llc | Novel mek inhibitors, useful in the treatment of diseases |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
KR101821768B1 (en) | 2009-11-05 | 2018-01-24 | 리젠 파마슈티컬스 소시에떼 아노님 | Novel benzopyran kinase modulators |
CA2789629A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc. | Cd20 antibodies and uses thereof |
DK2534153T3 (en) | 2010-02-12 | 2017-01-09 | Pfizer | Salts and polymorphs of 8-fluoro-2- {4 - [(methylamino} methyl] phenyl} -1,3,4,5-tetrahydro-6H-azepino [5,4,3-cd] indole-6-one |
WO2011109584A2 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
AU2011223643A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
CN107674073B (en) | 2010-05-17 | 2021-09-10 | 印蔻真治疗公司 | 3, 5-disubstituted-3H-imidazo [4,5-B ] pyridine compounds as modulators of protein kinases |
CN103002738A (en) | 2010-05-21 | 2013-03-27 | 英特利凯恩有限责任公司 | Chemical compounds, compositions and methods for kinase modulation |
AU2011268356B2 (en) | 2010-06-16 | 2013-09-19 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Antibodies to endoplasmin and their use |
EP2630134B9 (en) | 2010-10-20 | 2018-04-18 | Pfizer Inc | Pyridine-2- derivatives as smoothened receptor modulators |
EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
MX347708B (en) | 2011-01-10 | 2017-05-09 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones. |
WO2012106556A2 (en) | 2011-02-02 | 2012-08-09 | Amgen Inc. | Methods and compositons relating to inhibition of igf-1r |
AU2012231640B2 (en) | 2011-02-15 | 2015-07-09 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
WO2012142164A1 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii |
EP3536708A1 (en) | 2011-04-19 | 2019-09-11 | Pfizer Inc | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
US9775841B2 (en) | 2011-05-04 | 2017-10-03 | Rhizen Pharmaceuticals Sa | Compounds as modulators of protein kinases |
CN107737100A (en) | 2011-06-14 | 2018-02-27 | 哈尔生物药投资有限责任公司 | The administration of Benzodiazepine composition |
MX2014000648A (en) | 2011-07-19 | 2014-09-25 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof. |
JP6027610B2 (en) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | Heterocyclic compounds and uses thereof |
PT3409278T (en) | 2011-07-21 | 2020-12-18 | Sumitomo Dainippon Pharma Oncology Inc | Heterocyclic protein kinase inhibitors |
SG11201400310WA (en) | 2011-08-29 | 2014-06-27 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
PE20141228A1 (en) | 2011-09-22 | 2014-10-01 | Pfizer | DERIVATIVES OF PYRROLOPYRIMIDINE AND PURINE |
US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
JP2014528963A (en) * | 2011-10-04 | 2014-10-30 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラルシェルシェ メディカル)Inserm(Institut National Dela Sante Etde La Recherche Medicale) | Novel apoptosis-inducing compound |
WO2013050725A1 (en) | 2011-10-04 | 2013-04-11 | King's College London | Ige anti -hmw-maa antibody |
RU2014114015A (en) | 2011-11-08 | 2015-12-20 | Пфайзер Инк. | METHODS FOR TREATING INFLAMMATORY DISORDERS USING ANTIBODIES AGAINST M-CSF |
WO2013126617A1 (en) | 2012-02-22 | 2013-08-29 | The Regents Of The University Of Colorado, A Body Corporate | Bouvardin derivatives and therapeutic uses thereof |
US9452215B2 (en) | 2012-02-22 | 2016-09-27 | The Regents Of The University Of Colorado | Bourvadin derivatives and therapeutic uses thereof |
CA2865719C (en) | 2012-03-30 | 2020-09-22 | Rhizen Pharmaceuticals Sa | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3505534A1 (en) | 2012-06-08 | 2019-07-03 | Sutro Biopharma, Inc. | Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use |
DK2863955T3 (en) | 2012-06-26 | 2017-01-23 | Sutro Biopharma Inc | MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF |
EP2887965A1 (en) | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
BR112015004022B1 (en) | 2012-08-31 | 2023-04-25 | Sutro Biopharma, Inc | MODIFIED AMINO ACIDS COMPRISING AN AZID GROUP |
DK2909181T3 (en) | 2012-10-16 | 2017-11-20 | Tolero Pharmaceuticals Inc | PKM2 modulators and methods for their use |
JP6584952B2 (en) | 2012-11-01 | 2019-10-02 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | Treatment of cancer using PI3 kinase isoform modulator |
EP3566750A3 (en) | 2013-02-28 | 2020-04-08 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
EP2961435B1 (en) | 2013-02-28 | 2019-05-01 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
MX2015012062A (en) | 2013-03-14 | 2016-05-05 | Tolero Pharmaceuticals Inc | Jak2 and alk2 inhibitors and methods for their use. |
EP2970121B1 (en) | 2013-03-15 | 2017-12-13 | Araxes Pharma LLC | Covalent inhibitors of kras g12c |
NZ629037A (en) | 2013-03-15 | 2017-04-28 | Infinity Pharmaceuticals Inc | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | Combination of kinase inhibitors and uses thereof |
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
WO2014143659A1 (en) | 2013-03-15 | 2014-09-18 | Araxes Pharma Llc | Irreversible covalent inhibitors of the gtpase k-ras g12c |
MX2015016277A (en) | 2013-05-30 | 2016-08-11 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators. |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
ES2658039T3 (en) | 2013-07-10 | 2018-03-08 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods for their preparation and methods of use |
JP6427197B2 (en) | 2013-10-03 | 2018-11-21 | クラ オンコロジー, インコーポレイテッド | Inhibitors of ERK and methods of use |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2021012208A (en) | 2013-10-04 | 2023-01-19 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof. |
EP3636639A1 (en) | 2013-10-10 | 2020-04-15 | Araxes Pharma LLC | Inhibitors of kras g12c |
JO3805B1 (en) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | Inhibitors of kras g12c |
WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
WO2015061204A1 (en) | 2013-10-21 | 2015-04-30 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
UA115388C2 (en) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders |
WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
TN2016000459A1 (en) | 2014-04-30 | 2018-04-04 | Pfizer | Cycloalkyl-linked diheterocycle derivatives. |
HUE042390T2 (en) | 2014-06-19 | 2019-06-28 | Ariad Pharma Inc | Heteroaryl compounds for kinase inhibition |
WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
JP6811706B2 (en) | 2014-07-31 | 2021-01-13 | ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー | Human monoclonal antibodies against EPHA4 and their use |
JO3556B1 (en) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
JP2017528498A (en) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Inhibitors of KRAS G12C mutant protein |
WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
EP3233829B1 (en) | 2014-12-18 | 2019-08-14 | Pfizer Inc | Pyrimidine and triazine derivatives and their use as axl inhibitors |
JP2018513853A (en) | 2015-04-10 | 2018-05-31 | アラクセス ファーマ エルエルシー | Substituted quinazoline compounds and methods of use thereof |
CA2982360A1 (en) | 2015-04-15 | 2016-10-20 | Liansheng Li | Fused-tricyclic inhibitors of kras and methods of use thereof |
EP3611506B1 (en) | 2015-04-20 | 2021-11-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Predicting response to alvocidib by mitochondrial profiling |
EP3288957A4 (en) | 2015-05-01 | 2019-01-23 | Cocrystal Pharma, Inc. | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
PL3298021T3 (en) | 2015-05-18 | 2019-11-29 | Tolero Pharmaceuticals Inc | Alvocidib prodrugs having increased bioavailability |
AR104020A1 (en) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | METHODS AND COMPOSITIONS TO INHIBIT THE INTERACTION OF MENINA WITH MILL PROTEINS |
WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
US10568887B2 (en) | 2015-08-03 | 2020-02-25 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058792A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
WO2017058805A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3364977A4 (en) | 2015-10-19 | 2019-09-04 | Araxes Pharma LLC | Method for screening inhibitors of ras |
AU2016355433C1 (en) | 2015-11-16 | 2021-12-16 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
CN108601752A (en) | 2015-12-03 | 2018-09-28 | 安吉奥斯医药品有限公司 | MAT2A inhibitor for treating MTAP deletion form cancers |
US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
KR20180104106A (en) | 2016-01-27 | 2018-09-19 | 서트로 바이오파마, 인크. | an anti-CD74 antibody conjugate, a composition comprising an anti-CD74 antibody conjugate, and an anti-CD74 antibody conjugate |
MX2018011105A (en) | 2016-03-16 | 2018-11-22 | Kura Oncology Inc | Substituted inhibitors of menin-mll and methods of use. |
EP3429585B1 (en) | 2016-03-16 | 2021-11-24 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-mll and methods of use |
US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
AU2017263574B2 (en) | 2016-05-12 | 2022-11-17 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
WO2017201302A1 (en) | 2016-05-18 | 2017-11-23 | The University Of Chicago | Btk mutation and ibrutinib resistance |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
WO2018045379A1 (en) | 2016-09-02 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
WO2018064510A1 (en) | 2016-09-29 | 2018-04-05 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
EP3523289A1 (en) | 2016-10-07 | 2019-08-14 | Araxes Pharma LLC | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
EP3362471B1 (en) | 2016-12-19 | 2021-11-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Profiling peptides and methods for sensitivity profiling |
RS62456B1 (en) | 2016-12-22 | 2021-11-30 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
JP2020505395A (en) | 2017-01-26 | 2020-02-20 | アラクセス ファーマ エルエルシー | Fused N-heterocyclic compounds and methods of use |
US11059819B2 (en) | 2017-01-26 | 2021-07-13 | Janssen Biotech, Inc. | Fused hetero-hetero bicyclic compounds and methods of use thereof |
WO2018140512A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
WO2018137705A1 (en) | 2017-01-26 | 2018-08-02 | Zai Lab (Shanghai) Co., Ltd. | Cd47 antigen binding unit and uses thereof |
US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
WO2018175746A1 (en) | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
AU2018271990A1 (en) | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
EP3630747A1 (en) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Quinazoline derivatives as modulators of mutant kras, hras or nras |
CN110869357A (en) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Compounds and methods of use thereof for treating cancer |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
WO2019023316A1 (en) | 2017-07-26 | 2019-01-31 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
EP3679040B1 (en) | 2017-09-08 | 2022-08-03 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
JP7196160B2 (en) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー, インコーポレイテッド | Treatment Regimens for Cancers Insensitive to BCL-2 Inhibitors Using the MCL-1 Inhibitor Albocidib |
KR20200051802A (en) | 2017-09-18 | 2020-05-13 | 서트로 바이오파마, 인크. | Anti-folate receptor alpha antibody conjugates and uses thereof |
US11649251B2 (en) | 2017-09-20 | 2023-05-16 | Kura Oncology, Inc. | Substituted inhibitors of menin-MLL and methods of use |
US20200237766A1 (en) | 2017-10-13 | 2020-07-30 | Tolero Pharmaceuticals, Inc. | Pkm2 activators in combination with reactive oxygen species for treatment of cancer |
CA3082077A1 (en) | 2017-11-10 | 2019-05-16 | The Regents Of The University Of Michigan | Ash1l degraders and methods of treatment therewith |
CA3084809A1 (en) | 2017-12-07 | 2019-06-13 | The Regents Of The University Of Michigan | Nsd family inhibitors and methods of treatment therewith |
BR112020020246A8 (en) | 2018-04-05 | 2022-10-18 | Sumitomo Dainippon Pharma Oncology Inc | AXL KINASE INHIBITORS AND THEIR USE |
EP3788038B1 (en) | 2018-05-04 | 2023-10-11 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
EP3788053A1 (en) | 2018-05-04 | 2021-03-10 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
CA3099045A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
MX2020012731A (en) | 2018-06-01 | 2021-02-22 | Amgen Inc | Kras g12c inhibitors and methods of using the same. |
CN112533581A (en) | 2018-06-07 | 2021-03-19 | 密歇根大学董事会 | PRC1 inhibitors and methods of treatment therewith |
JP7357644B2 (en) | 2018-06-11 | 2023-10-06 | アムジエン・インコーポレーテツド | KRAS G12C inhibitors for treating cancer |
US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
JP2021530554A (en) | 2018-07-26 | 2021-11-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | Methods and ACVR1 Inhibitors for Treatment of Diseases with Abnormal ACVR1 Expression |
CA3107168A1 (en) | 2018-08-01 | 2020-02-06 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
US20220047716A1 (en) | 2018-09-17 | 2022-02-17 | Sutro Biopharma, Inc. | Combination therapies with anti-folate receptor antibody conjugates |
MX2021004624A (en) | 2018-10-24 | 2021-05-27 | Araxes Pharma Llc | 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1h-indazol-4-yl) -benzonitrile derivatives and related compounds as inhibitors of g12c mutant kras protein for inhibiting tumor metastasis. |
JP2020090482A (en) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Improved synthesis of key intermediate of kras g12c inhibitor compound |
WO2020106640A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
CA3120383A1 (en) | 2018-11-29 | 2020-06-04 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
AU2019391097A1 (en) | 2018-12-04 | 2021-05-20 | Sumitomo Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
JP2022514268A (en) | 2018-12-20 | 2022-02-10 | アムジエン・インコーポレーテツド | KIF18A inhibitor |
MX2021007157A (en) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroaryl amides useful as kif18a inhibitors. |
PE20211475A1 (en) | 2018-12-20 | 2021-08-05 | Amgen Inc | KIF18A INHIBITORS |
MX2021007158A (en) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroaryl amides useful as kif18a inhibitors. |
US11471456B2 (en) | 2019-02-12 | 2022-10-18 | Sumitomo Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
MX2021010319A (en) | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Bicyclic heteroaryl compounds and uses thereof. |
MX2021010323A (en) | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Bicyclic heterocyclyl compounds and uses thereof. |
JP2022525149A (en) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | Treatment of Acute Myeloid Leukemia (AML) with Venetoclax Failure |
JP2022519923A (en) | 2019-03-22 | 2022-03-25 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | Compositions comprising a PKM2 modulator and methods of treatment using it |
WO2020227105A1 (en) | 2019-05-03 | 2020-11-12 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
EP3972973A1 (en) | 2019-05-21 | 2022-03-30 | Amgen Inc. | Solid state forms |
CN114302878A (en) | 2019-07-03 | 2022-04-08 | 大日本住友制药肿瘤公司 | Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof |
MX2022001296A (en) | 2019-08-02 | 2022-02-22 | Amgen Inc | Kif18a inhibitors. |
AU2020325115A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | Pyridine derivatives as KIF18A inhibitors |
US20220289724A1 (en) | 2019-08-02 | 2022-09-15 | Amgen Inc. | Kif18a inhibitors |
AU2020324963A1 (en) | 2019-08-02 | 2022-02-24 | Amgen Inc. | KIF18A inhibitors |
TW202126636A (en) | 2019-09-30 | 2021-07-16 | 美商阿吉歐斯製藥公司 | Piperidine compounds as menin inhibitors |
AU2020369569A1 (en) | 2019-10-24 | 2022-04-14 | Amgen Inc. | Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer |
WO2021086833A1 (en) | 2019-10-28 | 2021-05-06 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
EP4051266A1 (en) | 2019-10-31 | 2022-09-07 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
WO2021091982A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
US11739074B2 (en) | 2019-11-04 | 2023-08-29 | Revolution Medicines, Inc. | Ras inhibitors |
CR20220243A (en) | 2019-11-04 | 2022-08-04 | Revolution Medicines Inc | Ras inhibitors |
CR20220200A (en) | 2019-11-08 | 2022-07-28 | Revolution Medicines Inc | Bicyclic heteroaryl compounds and uses thereof |
US20230192682A1 (en) | 2019-11-14 | 2023-06-22 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
TW202132296A (en) | 2019-11-14 | 2021-09-01 | 美商安進公司 | Improved synthesis of kras g12c inhibitor compound |
WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
AU2021206217A1 (en) | 2020-01-07 | 2022-09-01 | Revolution Medicines, Inc. | SHP2 inhibitor dosing and methods of treating cancer |
WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
WO2021178597A1 (en) | 2020-03-03 | 2021-09-10 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
WO2021207310A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
WO2021204159A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
WO2021215545A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c |
US20230174518A1 (en) | 2020-04-24 | 2023-06-08 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
MX2022016355A (en) | 2020-06-18 | 2023-04-03 | Revolution Medicines Inc | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors. |
US11858925B2 (en) | 2020-07-10 | 2024-01-02 | The Regents Of The University Of Michigan | GAS41 inhibitors and methods of use thereof |
AU2021308045A1 (en) | 2020-07-15 | 2023-02-23 | Taiho Pharmaceutical Co., Ltd. | Pyrimidine compound-containing combination to be used in tumor treatment |
MX2023002248A (en) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Use of sos1 inhibitors to treat malignancies with shp2 mutations. |
JP2023541916A (en) | 2020-09-15 | 2023-10-04 | レボリューション メディシンズ インコーポレイテッド | Indole derivatives as RAS inhibitors in the treatment of cancer |
TW202237119A (en) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk-5 inhibitors and uses thereof |
AU2021409816A1 (en) | 2020-12-22 | 2023-07-06 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
BR112023022819A2 (en) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | COMPOUNDS, PHARMACEUTICAL COMPOSITION, CONJUGATES AND METHODS FOR TREATING CANCER IN A SUBJECT, FOR TREATING A DISORDER AND FOR INHIBITING A RAS PROTEIN IN A CELL |
KR20240017811A (en) | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | RAS inhibitors for the treatment of cancer |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2022250170A1 (en) | 2021-05-28 | 2022-12-01 | Taiho Pharmaceutical Co., Ltd. | Small molecule inhibitors of kras mutated proteins |
AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
WO2023056589A1 (en) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Menin inhibitors and methods of use for treating cancer |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023211812A1 (en) | 2022-04-25 | 2023-11-02 | Nested Therapeutics, Inc. | Heterocyclic derivatives as mitogen-activated protein kinase (mek) inhibitors |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024006542A1 (en) | 2022-06-30 | 2024-01-04 | Sutro Biopharma, Inc. | Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates |
WO2024010925A2 (en) | 2022-07-08 | 2024-01-11 | Nested Therapeutics, Inc. | Mitogen-activated protein kinase (mek) inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
ES2153031T4 (en) * | 1995-04-20 | 2001-05-16 | Pfizer | ARILSULFONIL HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF MMP AND TNF. |
US5753653A (en) | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
PL331802A1 (en) | 1996-08-28 | 1999-08-02 | Procter & Gamble | Substituted cyclic amines as metaloprotease inhibitors |
HUP0000591A3 (en) | 1996-08-28 | 2001-07-30 | Procter & Gamble | Piperazine, morpholine and thiomorpholine derivatives as metalloprotease inhibitors and use of them for producing pharmaceutical compositions |
EA002546B1 (en) * | 1997-02-11 | 2002-06-27 | Пфайзер Инк. | Arylsulfonyl hydroxamic acid derivatives |
JPH11199512A (en) * | 1997-10-24 | 1999-07-27 | Pfizer Prod Inc | Use of mmp-13 selective inhibitor for the treatment of arthrosis deformans and other mmp-mediated disease |
-
1998
- 1998-01-16 EA EA199900641A patent/EA002546B1/en not_active IP Right Cessation
- 1998-01-16 YU YU37499A patent/YU37499A/en unknown
- 1998-01-16 IL IL13112398A patent/IL131123A0/en not_active IP Right Cessation
- 1998-01-16 WO PCT/IB1998/000064 patent/WO1998034918A1/en not_active Application Discontinuation
- 1998-01-16 AU AU53366/98A patent/AU722784B2/en not_active Ceased
- 1998-01-16 JP JP53404098A patent/JP3710489B2/en not_active Expired - Fee Related
- 1998-01-16 BR BR9807678-7A patent/BR9807678A/en not_active Application Discontinuation
- 1998-01-16 EP EP98900124A patent/EP0960098A1/en not_active Withdrawn
- 1998-01-16 PL PL98334997A patent/PL334997A1/en unknown
- 1998-01-16 SK SK1013-99A patent/SK101399A3/en unknown
- 1998-01-16 KR KR1019997007188A patent/KR20000070923A/en not_active Application Discontinuation
- 1998-01-16 ID IDW990847A patent/ID22809A/en unknown
- 1998-01-16 NZ NZ336836A patent/NZ336836A/en unknown
- 1998-01-16 CA CA002280151A patent/CA2280151C/en not_active Expired - Fee Related
- 1998-01-16 HU HU0000657A patent/HUP0000657A3/en unknown
- 1998-01-16 CN CN98802460A patent/CN1247531A/en active Pending
- 1998-01-16 TR TR1999/01926T patent/TR199901926T2/en unknown
- 1998-01-26 HN HN1998000020A patent/HN1998000020A/en unknown
- 1998-02-02 GT GT199800026A patent/GT199800026A/en unknown
- 1998-02-05 AP APAP/P/1998/001179A patent/AP958A/en active
- 1998-02-06 PE PE1998000087A patent/PE58699A1/en not_active Application Discontinuation
- 1998-02-06 UY UY24880A patent/UY24880A1/en not_active IP Right Cessation
- 1998-02-09 TW TW087101709A patent/TW502020B/en not_active IP Right Cessation
- 1998-02-10 ZA ZA9801061A patent/ZA981061B/en unknown
- 1998-02-10 AR ARP980100582A patent/AR011123A1/en not_active Application Discontinuation
- 1998-02-10 MA MA24960A patent/MA24469A1/en unknown
- 1998-02-10 TN TNTNSN98025A patent/TNSN98025A1/en unknown
- 1998-02-10 DZ DZ980026A patent/DZ2416A1/en active
- 1998-02-11 CO CO98007136A patent/CO4950619A1/en unknown
- 1998-02-12 HR HR980070A patent/HRP980070B1/en not_active IP Right Cessation
- 1998-02-15 SA SA98180856A patent/SA98180856A/en unknown
- 1998-02-18 PA PA19988446101A patent/PA8446101A1/en unknown
-
1999
- 1999-07-23 IS IS5130A patent/IS5130A/en unknown
- 1999-08-05 BG BG103641A patent/BG63430B1/en active Active
- 1999-08-06 OA OA9900174A patent/OA11142A/en unknown
- 1999-08-10 NO NO993836A patent/NO993836L/en not_active Application Discontinuation
-
2000
- 2000-11-08 US US09/708,328 patent/US6599890B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ336836A (en) | Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments | |
CA2218503C (en) | Arylsulfonyl hydroxamic acid derivatives | |
AP733A (en) | Arylsulfonylamino hydroxamic acid derivatives. | |
KR100317146B1 (en) | Arylsulfonylamino Hydroxamic Acid Derivatives | |
KR20080109915A (en) | Organic compounds | |
EP0895988B1 (en) | Arylsulfonylamino hydroxamic acid derivatives | |
US6509337B1 (en) | Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors | |
MXPA99007385A (en) | Arylsulfonyl hydroxamic acid derivatives | |
KR100194258B1 (en) | Arylsulfonyl Hydroxamic Acid Derivatives | |
CZ20012711A3 (en) | Hydroxamic acid derivatives containing alkynyl group, their preparation and their use as inhibitors of intercellular material metalloproteinases (MMP) and inhibitors of TNF-alpha (TACE) converting enzyme | |
MXPA99001808A (en) | Arylsulfonylamino hydroxamic acid derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |